<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS141181</article-id>
<article-id pub-id-type="doi">10.1101/2021.12.20.473401</article-id>
<article-id pub-id-type="archive">PPR434810</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Arsenal of Nanobodies for Broad-Spectrum Countermeasures against Current and Future SARS-CoV-2 Variants of Concerns</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Rossotti</surname>
<given-names>M. A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van Faassen</surname>
<given-names>H.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tran</surname>
<given-names>A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sheff</surname>
<given-names>J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sandhu</surname>
<given-names>J. K.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Duque</surname>
<given-names>D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hewitt</surname>
<given-names>M.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wen</surname>
<given-names>S.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bavananthasivam</surname>
<given-names>R.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Beitari</surname>
<given-names>S.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Matte</surname>
<given-names>K.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Laroche</surname>
<given-names>G.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Giguère</surname>
<given-names>P. M.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gervais</surname>
<given-names>C.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stuible</surname>
<given-names>M.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guimond</surname>
<given-names>J.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Perret</surname>
<given-names>S.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hussack</surname>
<given-names>G.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Langlois</surname>
<given-names>M.-A.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Durocher</surname>
<given-names>Y.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tanha</surname>
<given-names>J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada, 100 Sussex Drive, Ottawa, Ontario, Canada</aff>
<aff id="A2">
<label>2</label>Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada, 1200 Montreal Road, Ottawa, Ontario, Canada</aff>
<aff id="A3">
<label>3</label>Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Ottawa, Ontario, Canada</aff>
<aff id="A4">
<label>4</label>University of Ottawa Brain and Mind Research Institute, University of Ottawa, 451 Smyth Road, Ottawa, Ontario, Canada</aff>
<aff id="A5">
<label>5</label>Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada, 6100 Royalmount Avenue, Montréal, Québec, Canada</aff>
<aff id="A6">
<label>6</label>Département de biochimie et médecine moléculaire, Université de Montréal, Pavillon Roger-Gaudry, C.P. 6128, Succ. Centre-ville, Montréal, Québec, Canada</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>Correspondence to: Jamshid Tanha, Ph.D., Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada, 100 Sussex Drive, Ottawa, Ontario, Canada, K1A 0R6, Tel: 613-990-7206; <email>Jamshid.Tanha@nrc-cnrc.gc.ca</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>07</day>
<month>02</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="preprint">
<day>21</day>
<month>12</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">Nanobodies offer several potential advantages over mAbs for the control of SARS-CoV-2. Their ability to access cryptic epitopes conserved across SARS-CoV-2 variants of concern (VoCs) and feasibility to engineer modular, multimeric designs, make these antibody fragments ideal candidates for developing broad-spectrum therapeutics against current and continually emerging SARS-CoV-2 VoCs. Here we describe a diverse collection of 37 anti-SARS-CoV-2 spike glycoprotein nanobodies extensively characterized as both monovalent and IgG Fc-fused bivalent modalities. The panel of nanobodies were shown to have high intrinsic affinity; high thermal, thermodynamic and aerosolization stability; broad subunit/domain specificity and cross-reactivity across many VoCs; wide-ranging epitopic and mechanistic diversity; high and broad <italic>in vitro</italic> neutralization potencies; and high neutralization efficacies in hamster models of SARS-CoV-2 infection, reducing viral burden by up to six orders of magnitude to below detectable levels. <italic>In vivo</italic> protection was demonstrated with anti-RBD and previously unreported anti-NTD and anti-S2 nanobodies. This collection of nanobodies provides a therapeutic toolbox from which various cocktails or multi-paratopic formats could be built to tackle current and future SARS-CoV-2 variants and SARS-related viruses. Furthermore, the high aerosol-ability of nanobodies provides the option for effective needle-free delivery through inhalation.</p>
</abstract>
<kwd-group>
<kwd>SARS-CoV-2</kwd>
<kwd>Variant of concern</kwd>
<kwd>Spike glycoprotein</kwd>
<kwd>NTD</kwd>
<kwd>S2</kwd>
<kwd>V<sub>H</sub>H</kwd>
<kwd>Nanobody</kwd>
<kwd>Therapy</kwd>
<kwd>Diagnosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P2">Declared a pandemic in March 2020 by the World Health Organization (covid19.who.int), coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a severe global health and economic burden. As of 20 December, 2021, 275 million individuals have been infected world-wide, of which ~5.5 million have died (coronavirus.jhu.edu). The toll on public health has been exacerbated with the continual emergence of SARS-CoV-2 variants of concern (VoCs) <sup>
<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref>
</sup>. These VoCs, which include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529), can evade COVID-19 vaccines and therapeutics to different extents, and the evolutionary trajectory of the virus variants predicts newer VoC escape mutants to emerge in the future <sup>
<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R8">8</xref>
</sup>.</p>
<p id="P3">Key to SARS-CoV-2 infection is its surface-displayed spike glycoprotein (S) <sup>
<xref ref-type="bibr" rid="R9">9</xref>–<xref ref-type="bibr" rid="R13">13</xref>
</sup>, a homotrimeric protein where each protomer ectodomain format consists of S1 and S2 subunits. S1 is further delineated by an N-terminal domain (NTD), a receptor-binding domain (RBD) and subdomains SD1 and SD2. The spike glycoprotein mediates cell entry, a critical first phase in the infection process, involving two discrete but concerted steps. In the first, virus-cell binding step, the RBD, essentially through its receptor-binding motif (RBM), binds to its host receptor angiotensin-converting enzyme II (ACE2). This is followed by the second, virus-cell fusion step, which is mediated by the S2 subunit and concludes the viral cell entry event. Spike glycoprotein is the primary target for COVID-19 therapeutic antibodies, which operate by stopping virus cell entry <italic>via</italic> blocking the cell binding and/or fusion step. In particular, the mechanism of action of most potent neutralizing antibodies involves binding to the RBD, although neutralizing antibodies targeting the NTD domain <sup>
<xref ref-type="bibr" rid="R14">14</xref>–<xref ref-type="bibr" rid="R19">19</xref>
</sup> and the S2 subunit <sup>
<xref ref-type="bibr" rid="R20">20</xref>, <xref ref-type="bibr" rid="R21">21</xref>
</sup> have also been reported.</p>
<p id="P4">While many COVID-19 immunotherapies are based on monoclonal antibodies (mAbs), single-domain antibodies (mostly V<sub>h</sub>Hs) are also being pursued as alternative therapeutics <sup>
<xref ref-type="bibr" rid="R22">22</xref>–<xref ref-type="bibr" rid="R48">48</xref>
</sup>. V<sub>h</sub>Hs (nanobodies) are the variable domains of camelid heavy-chain antibodies responsible for antigen recognition. One nanobody (VHH-72/XVR011) has already entered clinical trials for COVID-19 therapy <sup>
<xref ref-type="bibr" rid="R29">29</xref>, <xref ref-type="bibr" rid="R39">39</xref>, <xref ref-type="bibr" rid="R49">49</xref>
</sup>. V<sub>h</sub>Hs offer potential advantages over mAbs as COVID-19 immunotherapeutics, most notably because of their stability against aerosolization that allows for convenient, low-cost and effective needle-free delivery of V<sub>h</sub>Hs into the key site of infection (lungs) by inhalation <sup>
<xref ref-type="bibr" rid="R40">40</xref>, <xref ref-type="bibr" rid="R41">41</xref>, <xref ref-type="bibr" rid="R50">50</xref>–<xref ref-type="bibr" rid="R52">52</xref>
</sup>. Importantly, V<sub>h</sub>Hs permit modular assembly of multimeric/multi-paratopic nanobody constructs with drastically improved efficacy and cross-reactivity/neutralization breadth across VoCs <sup>
<xref ref-type="bibr" rid="R34">34</xref>, <xref ref-type="bibr" rid="R36">36</xref>
</sup>. Multispecific V<sub>h</sub>H constructs can also be designed to target confined geometric spaces on the surface of the target antigen without nanobody clash, a feature not achievable with larger mAbs. Critically, with small size and frequently extended CDR3s, V<sub>h</sub>Hs can reach cryptic epitopes that are hidden from mAbs and conserved across SARS-CoV-2 VoCs, allowing for the development of broad-spectrum nanobody therapeutics against current and future VoCs <sup>
<xref ref-type="bibr" rid="R34">34</xref>, <xref ref-type="bibr" rid="R39">39</xref>, <xref ref-type="bibr" rid="R40">40</xref>
</sup>.</p>
<p id="P5">Here we report the isolation, extensive characterization and <italic>in vivo</italic> efficacy of a large panel of SARS-CoV-2-targeting nanobodies. Monovalent V<sub>h</sub>H and bivalent V<sub>h</sub>H-Fc formats were assessed for binding affinity; thermal, thermodynamic and aerosol stability; epitopic diversity; S subunit/domain specificity; cross-reactivity to multiple betacoronavirus subgenera and VoCs; <italic>in vitro</italic> cross-neutralization potencies against several VoCs; and <italic>in vivo</italic> neutralization efficacies using a hamster model of infection. Multiple neutralization mechanisms of action are possible through V<sub>h</sub>H binding to RBD, NTD, and S2, including inhibiting the virus-cell binding and/or fusion steps. This robust collection of nanobodies provides a foundation for development of effective broad-spectrum therapeutics (monotherapy, cocktails or multimerics/multi-paratopics) that could tackle current and future SARS-CoV-2 variants and SARS-related viruses.</p>
</sec>
<sec id="S2" sec-type="results">
<label>2</label>
<title>Results</title>
<sec id="S3">
<label>2.1</label>
<title>Llama immunization and serum analyses</title>
<p id="P6">Prior to immunization, serology and panning experiments, purified SARS-CoV-2 spike glycoprotein (S) antigens were validated for functionality in adsorbed/captured states on microtiter wells (<xref ref-type="supplementary-material" rid="SD1">Fig. S1</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S1</xref>). Two llamas (Green &amp; Red) were immunized with SARS-CoV-2 Wuhan-Hu-1 (Wuhan) S fragments. Specifically, Green was primed with S and boosted with three doses of RBD fragment, while Red received four doses of S. Both llamas produced a strong and specific immune response to S, S1, S2 and RBD with Green consistently outperforming Red (up to 10-fold) across all four target proteins (<xref ref-type="supplementary-material" rid="SD1">Fig. S2A</xref>). Analyses of total polyclonal sera by flow cytometry-based surrogate neutralization assays (SVNA) showed a more potent neutralizing antibody response generated by Green (<xref ref-type="supplementary-material" rid="SD1">Fig. S2B</xref>).</p>
</sec>
<sec id="S4">
<label>2.2</label>
<title>Phage display library construction, selection and screening</title>
<p id="P7">Two phage display libraries, Green and Red, were constructed using day 28 peripheral blood mononuclear cells (PBMCs) and separately subjected to two rounds of panning against S fragments. To further maximize for V<sub>h</sub>H diversity, panning was performed under multiple selection conditions (P1 – P6; see Methods) to direct selection towards S-, S1-, S2-, RBD-, NTD- and RBM-specific binders. Monoclonal phage ELISA combined with DNA sequencing identified 37 unique V<sub>h</sub>Hs across all screens (<xref ref-type="fig" rid="F1">Fig. 1A; Fig. 1B</xref>). Most V<sub>h</sub>Hs originated from llama Green, 26 <italic>vs</italic> 11 from llama Red (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). Llama Green, which was predominantly immunized with RBD, yielded a higher proportion of RBD-specific V<sub>h</sub>Hs (15 RBD, six NTD, five S2) compared to llama Red which was immunized with only S and yielded mostly S2-specific V<sub>h</sub>Hs (two RBD, three NTD, six S2).</p>
<p id="P8">Selected V<sub>h</sub>Hs were then (i) cloned as fusions to the biotinylation acceptor peptide (BAP) and His6 tags and produced in <italic>E. coli</italic>; and (ii) cloned in fusion with human IgG1 hinge-Fc domain (V<sub>h</sub>H-Fc) and produced in HEK293-6E cells.</p>
</sec>
<sec id="S5">
<label>2.3</label>
<title>Binding characteristics of V<sub>h</sub>Hs and V<sub>h</sub>H-Fcs</title>
<p id="P9">V<sub>h</sub>Hs/V<sub>h</sub>H-Fcs were tested by SPR and ELISA against recombinant Wuhan SARS-CoV-2 S, S1, RBD, NTD and S2 proteins to determine affinities and subunit/domain specificities (<xref ref-type="fig" rid="F1">Fig. 1C</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S3</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S2</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S3</xref>). V<sub>h</sub>Hs bound with high affinity, with the majority of <italic>K</italic>
<sub>d</sub>s in the single-digit-nM to pM range. Three clusters of V<sub>h</sub>Hs were identified: 17 RBD-specific V<sub>h</sub>Hs, nine NTD-specific V<sub>h</sub>Hs (no reactivity to RBD, bound S and S1) and 11 S2-specific V<sub>h</sub>Hs (<xref ref-type="fig" rid="F1">Fig. 1C</xref>). The domain specificity of the NTD binders was confirmed in subsequent ELISAs (<xref ref-type="supplementary-material" rid="SD1">Fig S3B</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S3</xref>). By flow cytometry, V<sub>h</sub>H-Fcs bound SARS-CoV-2 S (Wuhan) in a more natural context on the cell membrane of CHO cells (CHO<sup>55E1</sup>™) stably transfected with the S protein (<xref ref-type="fig" rid="F1">Fig. 1D</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S4</xref>; <xref ref-type="table" rid="T1">Table 1</xref>). High apparent affinities (<italic>EC</italic>
<sub>50</sub>apps) in the single-digit-nM to pM range were observed for the majority of V<sub>h</sub>H-Fcs.</p>
<p id="P10">V<sub>h</sub>Hs were examined for cross-reactivity to a collection of spike glycoprotein fragments from various coronavirus genera and SARS-CoV-2 variants by ELISA and SPR. In ELISA (<xref ref-type="fig" rid="F2">Fig. 2A</xref>; <xref ref-type="table" rid="T1">Table 1</xref>), many V<sub>h</sub>H-Fcs cross-reacted with the S protein from VoCs Alpha, Beta, Gamma, Delta and Kappa (B.1.617.1; Variant Being Monitored [VBM]). The exceptions were: 1) RBD-specific V<sub>h</sub>Hs 02/05 and 04/14/15 did not cross-react with Beta and Gamma, and Kappa, respectively, and 2) S2-specific V<sub>h</sub>Hs MRed18 and MRed19 did not cross-react with Kappa. All nine NTD-specific V<sub>h</sub>Hs cross-reacted with all variants tested. Additionally, many V<sub>h</sub>Hs cross-reacted with pangolin CoV, with fewer cross-reacting to SARS-CoV, SARS-like CoV WIV1, bat SARS-like CoV and civet SARS CoV. These viruses, including variants, are all of the Betacoronavirus Sarbecovirus subgenus. None of the antibodies tested cross-reacted with the remaining 11 non-Sarbecovirus Betacoronavirus, Alphacoronavirus, Deltacoronavirus or Gammacoronavirus. The broadly cross-reactive antibodies included V<sub>h</sub>Hs targeting all three regions of the S protein (RBD, NTD, S2). The most broadly cross-reactive V<sub>h</sub>Hs recognizing 10 – 11 viruses, including SARS-CoV-2 variants, were two NTD binders (SR01, SR02), six RBD binders (1d, 07, 11, 12, 20, MRed04) and six S2 binders (S2F3, S2G3, S2G4, MRed18, MRed19, MRed20). The VHH-72 benchmark was also broadly cross-reactive. The panel of V<sub>h</sub>Hs had similar cross-reactivity profiles to human ACE2, except that ACE2 did not bind civet SARS-CoV S and, unsurprisingly, bound HCoV-NL63 S (<xref ref-type="fig" rid="F2">Fig. 2A</xref>) <sup>
<xref ref-type="bibr" rid="R53">53</xref>, <xref ref-type="bibr" rid="R54">54</xref>
</sup>.</p>
<p id="P11">When tested by SPR against SARS-CoV, 11 out of 14 ELISA-positive V<sub>h</sub>Hs cross-reacted with SARS-CoV S, most with comparably high affinities (<xref ref-type="fig" rid="F2">Fig. 2B</xref>; <xref ref-type="table" rid="T1">Table 1</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S5A</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S4</xref>). Seven of these V<sub>h</sub>Hs were S2-specific, three RBD-specific and one NTD-specific. Against the Alpha and Beta variants, the SPR cross-reactivity data, performed with all RBD, all NTD and five S2 V<sub>h</sub>Hs (31 V<sub>h</sub>Hs), were consistent with ELISA, except for 04 and 14 which were negative or very weak for binding to the Beta variant by SPR. All 31 V<sub>h</sub>Hs bound the Alpha variant S protein, 28 of which were also cross-reactive to the Beta variant S protein (<xref ref-type="fig" rid="F2">Fig. 2C</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig S5B</xref>; <xref ref-type="table" rid="T1">Table 1</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S4</xref>). Thirteen out of 17 RBD-specific V<sub>h</sub>Hs bound all three variants with similar affinities, except for V<sub>h</sub>Hs 10, 15 and 17 which bound to the Beta variant with 40 – 50-fold weaker affinity; the remaining four that did not bind the Beta variant showed cross-reactivity with the Alpha variant with similar (04, 14) or reduced (~5-fold [05] and ~20-fold [02]) affinity relative to the Wuhan variant. All nine NTD-specific and five S2-specific V<sub>h</sub>Hs cross-reacted with the three variants with essentially the same affinities. The loss of binding for some of the ELISA-positive nanobodies in SPR assays could be due to the loss of binding avidity (V<sub>h</sub>H-Fc was used in ELISA <italic>vs</italic> V<sub>h</sub>H in SPR) and/or epitope hindrance on the sensorchip. In agreement with this, V<sub>h</sub>H 20 (ELISA<sup>+</sup>/SPR<sup>−</sup>) neutralizes SARS-CoV in surrogate virus neutralization assays (<italic>see</italic> below) as a V<sub>h</sub>H-Fc format; so do V<sub>h</sub>H-Fc 18 and SR13 which were false negatives by both ELISA and SPR, additionally demonstrating the number of SARS-CoV cross-reacting V<sub>h</sub>Hs exceeds that gleaned from the ELISA and SPR data.</p>
</sec>
<sec id="S6">
<label>2.4</label>
<title>Stability characteristics of V<sub>h</sub>Hs</title>
<p id="P12">By size exclusion chromatography (SEC), all tested V<sub>h</sub>Hs were aggregation-resistant (<xref ref-type="fig" rid="F3">Fig. 3A</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S6</xref>). V<sub>h</sub>Hs were highly thermostable: with the exception of V<sub>h</sub>H 11, MRed25 and S2A3 and which had <italic>T</italic>
<sub>m</sub>s of ~ 60 – 61°C, the remaining 30 V<sub>h</sub>Hs had higher <italic>T</italic>
<sub>m</sub>s of ~65 – 80°C (median: 70.4°C) (<xref ref-type="fig" rid="F3">Fig. 3B</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S7</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S5</xref>). Conformational stability of V<sub>h</sub>Hs was determined by measuring free energy of unfolding (Δ<italic>G</italic>
<sup>0</sup>) in GdnHCl equilibrium denaturation experiments, with Δ<italic>G</italic>
<sup>0</sup> ranging from 21.4 – 53.4 kJ/mol (median: 30.7 kJ/mol), and an <italic>m</italic> value range of 10.3 – 19.8 kJ/M*mol (median: 14.6 kJ/M*mol) observed (<xref ref-type="fig" rid="F3">Fig. 3C</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S8</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S5</xref>) <sup>
<xref ref-type="bibr" rid="R55">55</xref>–<xref ref-type="bibr" rid="R59">59</xref>
</sup>.</p>
<p id="P13">Since we planned to test V<sub>h</sub>H-Fcs in hamsters for <italic>in vivo</italic> efficacy, we pre-emptively assessed their <italic>in vivo</italic> stability and persistence. We chose 1d V<sub>h</sub>H-Fc as a representative and included VHH-72 V<sub>h</sub>H-Fc, whose modified/enhanced version is currently in a phase 1 clinical trial, as a reference. Hamsters were injected intraperitoneally (IP) with 1 mg of each antibody and serum antibody concentration was monitored for up to four days by ELISA. Significant and comparable V<sub>h</sub>H-Fc concentrations were present in the hamster sera for both 1d and VHH-72 V<sub>h</sub>H-Fcs on days 1 and 4 post injection (<xref ref-type="fig" rid="F3">Fig. 3D</xref>), indicating V<sub>h</sub>H-Fcs would have the required serum stability and persistence <italic>in vivo</italic> for the duration of the animal studies.</p>
<p id="P14">V<sub>h</sub>Hs were also examined for their aggregation resistance and stability upon aerosolization. For a few V<sub>h</sub>Hs, aerosolization induced soluble aggregate formation as determined by SEC, while for others it led to the formation of visible aggregates (<xref ref-type="supplementary-material" rid="SD1">Fig. S9</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S6</xref>). This resulted in reduced % recoveries, measures of V<sub>h</sub>H stability against aerosolization, and corresponding to the proportion of V<sub>h</sub>Hs that remained as soluble monomer following aerosolization (<xref ref-type="fig" rid="F3">Fig. 3E</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S9</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S6</xref>). The majority of V<sub>h</sub>Hs (18 out of 28 V<sub>h</sub>Hs tested), however, were stable against aerosolization with high % recoveries (<xref ref-type="fig" rid="F3">Fig. 3E</xref>). Additionally, several V<sub>h</sub>Hs still showed a high % recovery upon aerosolization (50 – 70 %) despite the formation of some visible aggregates. Comparison of ELISA-derived <italic>EC</italic>
<sub>50</sub>s of select pre-aerosolized <italic>vs</italic> post-aerosolized V<sub>h</sub>Hs clearly demonstrated aerosolization did not compromise the binding activities of V<sub>h</sub>Hs (<xref ref-type="fig" rid="F3">Fig. 3E</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S9</xref>).</p>
</sec>
<sec id="S7">
<label>2.5</label>
<title>Screening for neutralizing V<sub>h</sub>Hs by surrogate virus neutralization assays (SVNAs)</title>
<p id="P15">A preliminary screen of 25 V<sub>h</sub>Hs (14 RBD-specific, six NTD-specific and five S2-specfic) by ELISA- and SPR-based SVNAs identified several potential neutralizers, predominantly from the RBD-binding cohort (<xref ref-type="supplementary-material" rid="SD1">Fig. S10</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S7</xref>). A more relevant SVNA, which assessed the ability of antibodies to block binding of S to Vero E6 cells displaying ACE2, was then used as a screen to identify neutralizing V<sub>h</sub>Hs and V<sub>h</sub>H-Fcs. Neutralizing V<sub>h</sub>Hs displayed similar potencies (<italic>IC</italic>
<sub>50</sub>: 5 – 21 nM) and outperformed the benchmark VHH-72 (<italic>IC</italic>
<sub>50</sub>: 59 nM) by as much as 12-fold (<xref ref-type="supplementary-material" rid="SD1">Fig. S11</xref>; <xref ref-type="table" rid="T2">Table 2</xref>). Compared to V<sub>h</sub>Hs, a larger number of V<sub>h</sub>H-Fcs demonstrated neutralization capabilities (<xref ref-type="fig" rid="F4">Fig. 4A</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S12</xref>; <xref ref-type="table" rid="T2">Table 2</xref>). While neutralizing monomer V<sub>h</sub>Hs did not benefit from reformatting (except for the VHH-72 benchmark), several non-neutralizing V<sub>h</sub>Hs (three RBD-specific and three NTD-specific) benefitted profoundly from reformatting and were transformed into neutralizers that had potencies similar to other RBD-specific V<sub>h</sub>H-Fcs. All S2-specific V<sub>h</sub>Hs remained non-neutralizing as V<sub>h</sub>H-Fcs.</p>
<p id="P16">Extending our SVNAs to variants Alpha, Beta, Gamma, Delta and Kappa using all of the RBD-specific and a subset of NTD-specific V<sub>h</sub>H-Fcs (<xref ref-type="fig" rid="F4">Fig. 4B</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S8</xref>), several observations were made. First, for cross-neutralizing V<sub>h</sub>Hs the <italic>IC<sub>5</sub>0s</italic> across variants did not change significantly. Second, while all Wuhan neutralizers also remained Alpha neutralizers, some lost their capability to inhibit Beta, Gamma, Delta and Kappa with variable cross-neutralizing patterns. In particular, with respect to the RBD-specific V<sub>h</sub>Hs, the cross-neutralization profiles for Beta <italic>vs</italic> Gamma and Delta <italic>vs</italic> Kappa were identical, similarly reflective of the key escape mutations in these variants (K417N, E484K and N501Y for Beta <italic>vs</italic> K417T, E484K and N501Y for Gamma; L452R and T478K for Delta <italic>vs</italic> L452R and E484Q for Kappa). Third, and importantly, 12 out of 20 V<sub>h</sub>H-Fcs (10 RBD-specific, two NTD-specific) were Delta neutralizers, nine of which (eight RBD-specific, one NTD-specific) neutralized across all variants. The majority of these nine pan-neutralizers (six RBD-specific, one NTD-specific) also neutralized SARS-CoV.</p>
</sec>
<sec id="S8">
<label>2.6</label>
<title>Screening for neutralizing V<sub>h</sub>Hs by pseudotyped and live virus neutralization assays</title>
<p id="P17">Using a pseudotyped virus neutralization assay (PVNA), all 15 RBD-specific V<sub>h</sub>Hs tested were found to be neutralizing, and with the exception of 03 (<italic>IC</italic>
<sub>50</sub>: 0.91 μM) and 06 (<italic>IC</italic>
<sub>50</sub>: 2.5 μM), the V<sub>h</sub>Hs were potent neutralizers (<italic>IC</italic>
<sub>50</sub> range: 39 – 196 nM; median: 48 nM) (<xref ref-type="supplementary-material" rid="SD1">Fig. S13A</xref>; <xref ref-type="table" rid="T2">Table 2</xref>). For NTD-specific V<sub>h</sub>Hs, three of nine were neutralizing: two with similar <italic>IC</italic>
<sub>50</sub>s of 188 nM (SR01) and 269 nM (SR03) and one with an <italic>IC</italic>
<sub>50</sub> of 41 nM (SR13), comparable to the most potent RBD-specific V<sub>h</sub>Hs. Reformatting to V<sub>h</sub>H-Fc had a universal enhancing effect on neutralization potencies of V<sub>h</sub>Hs irrespective of epitope bin origin (<xref ref-type="fig" rid="F4">Fig. 4A</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S13B</xref>; <xref ref-type="table" rid="T2">Table 2</xref>). For RBD-specific V<sub>h</sub>Hs, potency increases (<italic>IC</italic>
<sub>50</sub> decreases) of 2 – 100-fold were observed; only one V<sub>h</sub>H (18) was unaffected with reformatting (<italic>IC</italic>
<sub>50</sub> range: 2.3 – 30.8 nM; median: 7.6 nM). NTD-specific V<sub>h</sub>H-Fcs demonstrated weaker potencies (<italic>IC</italic>
<sub>50</sub> range: 11.3 – 86.9 nM; median: 18.5 nM; 4 of 9 non-neutralizing). However, bivalency also significantly improved (~9-fold) the potencies of SR01 and SR03 and transformed a non-neutralizing V<sub>h</sub>H (SR16) into a potent neutralizing V<sub>h</sub>H-Fc. Consistent with the aforementioned SVNA results and previous data <sup>
<xref ref-type="bibr" rid="R29">29</xref>
</sup>, the VHH-72 benchmark also improved, elevated from a weak V<sub>h</sub>H (<italic>IC</italic>
<sub>50</sub>: 490 nM) to a strong V<sub>h</sub>H-Fc (25 nM) neutralizer. S2-specifiic V<sub>h</sub>Hs remained non-neutralizing with reformatting.</p>
<p id="P18">All RBD- and NTD-specific V<sub>h</sub>H-Fcs that were neutralizing by PVNA were also neutralizing in a live virus neutralization assay (LVNA) (<xref ref-type="fig" rid="F4">Fig. 4A</xref>; <xref ref-type="table" rid="T2">Table 2</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S14</xref>). However, compared to the former method, the LVNA <italic>IC</italic>
<sub>50</sub> values were lower and more variable. For RBD-specific V<sub>h</sub>H-Fcs an <italic>IC</italic>
<sub>50</sub> (range: 0.0008 – 76 nM; median: 2.8 nM) was observed. The most potent V<sub>h</sub>H-Fcs belonged to bin 2/3/4 (<italic>IC</italic>
<sub>50</sub> range: 0.0008 – 3.1 nM; median: 1 nM), with 05 showing the greatest potency (<italic>IC</italic>
<sub>50</sub>: 0.0008 nM) followed closely by 02 and MRed05 (<italic>IC</italic>
<sub>50</sub>s: 0.12 and 0.17 nM, respectively). Bin 1 neutralizers, to which VHH-72 belonged and displayed a similar <italic>IC</italic>
<sub>50</sub> (8.5 nM), exhibited intermediate potencies (range: 1.9 – 11.2 nM; median: 6.3 nM), followed by bin 5/6 neutralizers (range: 9.9 – 76 nM; median: 58 nM). Weaker neutralizing potencies were observed with NTD-specific V<sub>h</sub>H-Fcs. Here, six of nine V<sub>h</sub>H-Fcs, representing at least one epitope bin, were neutralizing. Interestingly, three new neutralizers emerged from the pool of S2-specific V<sub>h</sub>H-Fcs using the LVNA, with S2A3 the most potent.</p>
<p id="P19">The LVNAs were extended to include Alpha and Beta variants. With the exception of V<sub>h</sub>H-Fc 06, all remaining 16 RBD-specific Wuhan neutralizers maintained their ability to neutralize Alpha (<xref ref-type="table" rid="T2">Table 2</xref>: <xref ref-type="fig" rid="F4">Fig. 4C</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S15</xref>). Interestingly, many V<sub>h</sub>Hs from across different epitope bins showed improved <italic>IC</italic>
<sub>50</sub>s by as high as 15-fold. Except for 05, which despite showing a reduced potency towards the Alpha variant (∼40-fold) still exhibited the highest potency of all against the variant, the remaining V<sub>h</sub>Hs demonstrated comparable potencies. Of the 16 Wuhan/Alpha neutralizers, 13 also neutralized the Beta variant, with the majority (10 of 13) demonstrating comparable potencies and two (14 and 17) showing reductions (∼10-fold). Although from the most potent bin (2/3/4), 02, 04 and 05, consistent with the cross-reactivity data (<xref ref-type="fig" rid="F2">Fig. 2A</xref>), were completely abrogated presumably by the Beta mutations in the RBD (K417N, E484K, N501Y), several others including MRed05, 10 and 15 did retain their high neutralizing potencies against both Alpha and Beta variants. A similar trend was observed for the NTD-specific neutralizing V<sub>h</sub>Hs: against the Alpha variant, potencies either remained essentially the same as those for the Wuhan variant or improved, while against the Beta variant, potencies diminished. Nonetheless, SR01 and SR16 maintained respectable neutralization potencies against Beta. The potencies of S2-specific neutralizers (S2A3, S2G3, S2G4) were also decreased with variants. However, the lead S2A3 still maintained comparable potencies across all three variants (<italic>IC</italic>
<sub>50</sub> of 12.2 nM, 31 nM and 54 nM for Wuhan, Alpha and Beta [<xref ref-type="table" rid="T2">Table 2</xref>]). Collectively, the neutralization profiles across Wuhan, Alpha and Beta variants were consistent with cross-reactivity profiles (<xref ref-type="fig" rid="F2">Fig. 2A</xref>). Based on the cross-reactivity (<xref ref-type="fig" rid="F2">Fig. 2A</xref>) and surrogate cross-neutralization data (<xref ref-type="fig" rid="F4">Fig. 4B</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S8</xref>), it is likely that many V<sub>h</sub>Hs would also neutralize the Gamma, Kappa and Delta variants in LVNAs.</p>
</sec>
<sec id="S9">
<label>2.7</label>
<title>Epitope studies</title>
<p id="P20">To identify the number of non-overlapping epitopes, V<sub>h</sub>Hs were subjected to epitope binning experiments by SPR and sandwich ELISA. SPR assays were performed by injecting paired combinations of eight RBD-specific V<sub>h</sub>Hs, six NTD-specific V<sub>h</sub>Hs and ten S2-specific V<sub>h</sub>Hs over a SARS-CoV-2 spike glycoprotein surface (<xref ref-type="supplementary-material" rid="SD1">Fig. S16A</xref>). A conceptually similar assay to SPR was also performed by sandwich ELISA (<xref ref-type="supplementary-material" rid="SD1">Fig. S16B</xref>). From the 33 V<sub>h</sub>Hs tested, 14 unique epitope bins were identified: six for RBD-specific V<sub>h</sub>Hs, three for NTD-specific V<sub>h</sub>Hs and five for S2-specific V<sub>h</sub>Hs (<xref ref-type="fig" rid="F5">Fig. 5A</xref>; <xref ref-type="table" rid="T1">Table 1</xref>). The benchmark VHH-72 binned with RBD-specific V<sub>h</sub>Hs 1d, 07, 12, 18, 20 and MRed04. With the exception of V<sub>h</sub>H 04, all remaining bin 1, 2, 3 and 4 V<sub>h</sub>Hs (13 in total), as well as VHH-72, binned with ACE2, consistent with them being potent neutralizers. The results of sandwich ELISAs extended to include variants Alpha, Beta, Gamma, Delta and Kappa (<xref ref-type="supplementary-material" rid="SD1">Fig. S16C</xref>), using lead V<sub>h</sub>Hs from various bins as capture antibodies, were consistent with epitope binning as well as cross-reactivity (<xref ref-type="fig" rid="F2">Fig. 2A</xref>) data.</p>
<p id="P21">Next, we investigated the conformational nature of the epitope bins at peptide-level resolution with hydrogen-exchange mass spectrometry (HDX-MS) (<xref ref-type="supplementary-material" rid="SD2">Table S9</xref>). A summary of normalized HDX shifts are shown in <xref ref-type="fig" rid="F5">Fig. 5</xref>, and projected onto 3-D structures in <xref ref-type="supplementary-material" rid="SD1">Fig. S17</xref>. There is a strong agreement between HDX-MS profiles and previously described epitope bins and subunit/domain specificity. A common binding mode adjacent to the RBM and distant from known VoC mutations was observed for bin 1 (<xref ref-type="fig" rid="F5">Fig. 5B</xref>). This overlaps with core binding contacts of VHH-72 on SARS-CoV <sup>
<xref ref-type="bibr" rid="R29">29</xref>
</sup> where neutralization is achieved by steric blocking of ACE2. The binding profiles for the strongest neutralizers in bins 2/3/4 overlap the ACE2 binding site <sup>
<xref ref-type="bibr" rid="R10">10</xref>
</sup> and known conformational hotspots <sup>
<xref ref-type="bibr" rid="R60">60</xref>
</sup>. It was not possible to further resolve epitope diversity within the context of this dataset, however it is evident that a range of binding patterns exists <sup>
<xref ref-type="bibr" rid="R61">61</xref>, <xref ref-type="bibr" rid="R62">62</xref>
</sup>, and there is a correlation between stabilizations spanning mutations in VoCs and the loss/attenuation of neutralization (<xref ref-type="fig" rid="F5">Fig. 5B</xref>). Such granularity assists in understanding and predicting neutralization potency as novel variants emerge.</p>
<p id="P22">Epitopes for bin 6 (V<sub>h</sub>H 03 and 11) span the C-terminus of the RBD and SD1 <sup>
<xref ref-type="bibr" rid="R63">63</xref>
</sup> (<xref ref-type="fig" rid="F5">Fig. 5B</xref>), explaining why binding is limited to constructs containing SD1 (<xref ref-type="supplementary-material" rid="SD2">Table S2</xref>). Stabilization of the SD1 hinge responsible for RBD motion highlights a potential inhibitory mechanism for V<sub>h</sub>H 11 <sup>
<xref ref-type="bibr" rid="R64">64</xref>
</sup>. While it is challenging to delineate between an epitope and conformational effects based on HDX profiles alone, distinct binding responses with common conformational hotspots were observed for the NTD binders (<xref ref-type="fig" rid="F5">Fig. 5C</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S17</xref>). Interestingly, none of the NTD-supersite loops <sup>
<xref ref-type="bibr" rid="R14">14</xref>–<xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R19">19</xref>, <xref ref-type="bibr" rid="R65">65</xref>–<xref ref-type="bibr" rid="R67">67</xref>
</sup> covered here displayed significant HDX shifts, except for N4 stabilized by SR02, suggesting a range of binding modes beyond the NTD-supersite. Further, stabilizations partially overlap a previously described conformationally active epitope with low variability and neutralization vulnerability <sup>
<xref ref-type="bibr" rid="R15">15</xref>
</sup>. Supersite binders appear to be vulnerable to escape mutants <sup>
<xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R68">68</xref>
</sup>, highlighting the importance of targeting and characterizing alternative NTD epitopes.</p>
<p id="P23">An epitope for S2A3 spanning the linker/CD/HR2 motifs <sup>
<xref ref-type="bibr" rid="R21">21</xref>
</sup> is described in <xref ref-type="fig" rid="F5">Fig. 5D</xref>. This region is upstream of known S2 epitopes and is crucial for the structural transition required for virus-cell fusion <sup>
<xref ref-type="bibr" rid="R69">69</xref>
</sup>. We cannot rule out the involvement of other residues within CD/HR2 regions due to gaps in coverage. Given that none of the mutations within the six SARS-CoV-2 variants overlap the epitope, the cross-reactivity against the six variants (<xref ref-type="fig" rid="F2">Fig. 2A</xref>) and cross-neutralization against Alpha and Beta (<xref ref-type="table" rid="T2">Table 2</xref>), we predict similar neutralization potencies against the Gamma, Kappa and Delta variants.</p>
<p id="P24">Finally, epitope typing by denaturing SDS-PAGE and western blotting indicated 13 of the 37 V<sub>h</sub>Hs were recognizing linear epitopes, with the majority (9 out of 12) being S2-specific (<xref ref-type="table" rid="T1">Table 1</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig S18</xref>).</p>
</sec>
<sec id="S10">
<label>2.8</label>
<title>
<italic>In vivo</italic> therapeutic efficacy of V<sub>h</sub>H-Fcs</title>
<p id="P25">The <italic>in vivo</italic> therapeutic efficacy of V<sub>h</sub>H-Fcs which were neutralizing by LVNA were assessed in a hamster model of SARS-CoV-2 infection. Five V<sub>h</sub>H-Fcs were selected to cover a wide range of important attributes including <italic>in vitro</italic> neutralization potencies and breadth, epitope bin, subunit/domain specificity and cross-reactivity pattern. These included three RBD-specific (1d, 05, MRed05), one NTD-specific (SR01) and one S2-specific (S2A3) V<sub>h</sub>H-Fcs. Cocktails of two V<sub>h</sub>H-Fcs were also included to explore synergy between the antibody pairs recognizing distinct epitopes within the RBD (1d/MRed05) or RBD and NTD (1d/SR01).</p>
<p id="P26">Hamsters were administered IP with 1 mg of V<sub>h</sub>H-Fcs 24 h prior to intranasal challenge with SARS-CoV-2 Wuhan isolate. Daily weight change and clinical symptoms were monitored. At 5 dpi, lungs were collected to determine viral titers. Viral titer decrease and reversal of weight loss in antibody treated <italic>versus</italic> control animals were taken as measures of antibody efficacy. Animals treated with RBD binders 1d, 05, and MRed05 showed reduced lung viral burden by three, five and six orders of magnitude, respectively, relative to PBS or V<sub>h</sub>H-Fc isotype controls, with 05 and MRed05 reducing viral burden to below detectable levels (<xref ref-type="fig" rid="F6">Fig. 6A</xref>). The RBD-specific VHH-72 benchmark caused a mean viral decrease of four orders of magnitude. The NTD binder SR01, and interestingly, the S2 binder S2A3, were also effective neutralizers, decreasing mean viral titers by four and three orders of magnitude, respectively. Both 1d/SR01 and 1d/MRed05 cocktails decreased viral titers by 6 orders of magnitude to undetectable levels of virus infection. While it was not possible to unravel potential synergies for 1d/MRed05, as MRed05 alone displayed essentially the same efficacy as the 1d/MRed05 combination, it was apparent that the 1d/SR01 combination benefited from synergy, decreasing viral titers by a further 2 – 3 orders of magnitude to undetectable levels, relative to 1d or SR01 alone. Moreover, in accordance with the viral titer decreases, a gradual reversal of weight loss in infected animals was observed with antibody treatment starting on 2 dpi (<xref ref-type="fig" rid="F6">Fig. 6B,C</xref>). A strong negative correlation (r = −0.9436; p &lt;0.0001) was observed between weight change and viral titer at 5 dpi (<xref ref-type="fig" rid="F6">Fig. 6D</xref>).</p>
<p id="P27">Subsequent immunohistochemistry studies corroborated the viral titer and weight change results. First, in agreement with the viral titer observations, substantial viral antigen (nucleocapsid) reductions in hamster lungs were observed with antibody treatments (<xref ref-type="fig" rid="F6">Fig. 6E</xref>; compare non-treated PBS and isotype controls to treated profiles). Although, small foci of viral antigen expression were detected in VHH-72-, 1d-, SR01- and S2A3-treated animals, none were detected in 05-, MRed05-, 1d/SR01- and 1d/MRed05-treated animals. Second, SARS-CoV-2 infection is characterized by an overt inflammatory response in the respiratory tract accompanied by an increased infiltration of inflammatory immune cells, e.g., macrophages and T lymphocytes, in the lung parenchyma <sup>
<xref ref-type="bibr" rid="R70">70</xref>
</sup>. As expected, this was the case for the non-treated PBS and isotype control groups. In contrast, we observed a substantial reduction of macrophages and T lymphocytes infiltrate in lung parenchyma with antibody treatment (<xref ref-type="supplementary-material" rid="SD1">Fig. S19, S20</xref>). The most dramatic decreases in the number of macrophages and T lymphocytes were seen with 05, MRed05, 1d/MRed05 and 1d/SR01 treatments. Interestingly, a reduction in inflammatory responses was also associated with a decrease in the number of apoptotic cells in antibody-treated animals (<xref ref-type="supplementary-material" rid="SD1">Fig. S21</xref>). Altogether, the viral titer, weight change and immunohistochemistry results consistently demonstrate that a single dose of several of our V<sub>h</sub>H-Fcs reduced viral burden, immune cell infiltration and apoptosis in the lungs of infected hamsters.</p>
</sec>
</sec>
<sec id="S11" sec-type="discussion">
<label>3</label>
<title>Discussion</title>
<p id="P28">The efficacy of COVID-19 therapeutic antibodies and vaccines is persistently being threatened by emergence of new VoC escape mutants, presenting a pandemic state with no end in sight. Developing broad-spectrum antibodies that can neutralize current and emerging VoCs represents an effective countermeasure against the current SARS-CoV-2 pandemic and future ones.</p>
<p id="P29">Two key structural features of nanobodies make them promising candidates as broad-spectrum therapeutics. First is their ability to access epitopes on the surface of the spike glycoprotein that are hidden from mAbs and conserved across VoCs <sup>
<xref ref-type="bibr" rid="R34">34</xref>, <xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R45">45</xref>
</sup>. Second is their high modularity, allowing for their rapid conversion into multimeric/multi-paratopic constructs with favorable manufacturability profiles. Multimerization can lead to drastic increases in the efficacy of anti-COVID-19 nanobodies and broaden their cross-reactivity across variants <sup>
<xref ref-type="bibr" rid="R29">29</xref>, <xref ref-type="bibr" rid="R34">34</xref>, <xref ref-type="bibr" rid="R36">36</xref>, <xref ref-type="bibr" rid="R39">39</xref>
</sup>. Significantly, the chance of developing multimeric/multi-paratopic constructs with the desired cross-neutralization breadth improves with the diversity of nanobody building blocks available.</p>
<p id="P30">With the goal of developing broad-spectrum therapeutics, we employed multiple immunization, phage display library construction and panning strategies to identify a diverse collection of nanobodies. These were extensively characterized as monomeric V<sub>h</sub>Hs and homodimeric V<sub>h</sub>H-Fcs. Nanobodies were shown to have high intrinsic affinity (single-digit nM-pM); high thermal, thermodynamic and aerosolization stability; broad epitopic diversity falling into 14 different epitope clusters, broad subunit/domain specificity, recognizing NTD, RBD, and S2 regions; broad cross-reactivities recognizing up to 11 different Sarbecoviruses including several SARS-CoV-2 VoCs and high and broad <italic>in vitro</italic> and <italic>in vivo</italic> virus neutralization potencies/efficacies. Based on published results and our studies, a diversity of neutralization mechanisms of action can be envisaged for the anti-spike glycoprotein V<sub>h</sub>Hs, including inhibiting the ACE2-RBD interaction by direct competition, steric hindrance, locking the RBDs in the closed conformation and distorting the RBM, leading to inhibition of the virus-cell binding (RBD- and NTD-specific V<sub>h</sub>Hs) <sup>
<xref ref-type="bibr" rid="R38">38</xref>, <xref ref-type="bibr" rid="R71">71</xref>–<xref ref-type="bibr" rid="R73">73</xref>
</sup> and inhibiting conformational rearrangements leading to inhibition of virus-cell fusion (NTD- and S2-specific V<sub>h</sub>Hs) <sup>
<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R16">16</xref>, <xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R74">74</xref>
</sup>.</p>
<p id="P31">Our study also provides valuable insights into how various <italic>in vitro</italic> neutralization assays predict antibody efficacy. The flow cytometry-based SVNA was shown to effectively identify neutralizing antibodies that were RBD-specific, providing a viable alternative to the PVNA or LVNA, which are labor-intensive, difficult to standardize, inconvenient and not readily accessible as they require operating in biosafety level 2 or 3 labs. However, the SVNA occasionally missed NTD-specific neutralizing antibodies, and, similar to the PVNA, failed altogether to identify neutralizing antibodies that were S2-specific. Furthermore, the SVNA did not have the sensitivity of the LVNA to identify V<sub>h</sub>Hs with weaker potencies or, similar to the PVNA, to fine-rank neutralizing antibodies.</p>
<p id="P32">For several reasons, the number of epitope bins (14) identified in the current study likely under-estimates the number of actual distinct epitopes. First, V<sub>h</sub>Hs that recognize (i) partially overlapping epitopes, (ii) fully overlapping epitopes of significantly different nature, or (iii) non-overlapping epitopes, but manifest exclusive binding as a consequence of conformational competition or steric clashes between the V<sub>h</sub>H pairs, would fall under the same epitope bins. Second, indicators of distinct epitopes such as differential HDX-MS footprints, epitope types, cross-reactivity profiles, neutralization potencies, and cross-neutralization profiles not accounted for by affinity alone, are seen amongst V<sub>h</sub>Hs within the same bin. Thus, the repertoire of structurally and functionally distinct epitopes are more diverse than what can be gleaned from epitope binning analysis alone.</p>
<p id="P33">
<italic>In vitro</italic> neutralization assays with the Wuhan SARS-CoV-2 variant showed that the majority of the nanobodies were RBD-specific. Importantly, and to our knowledge for the first time, we demonstrated that several NTD- and S2-specific V<sub>h</sub>Hs were also potent and efficacious neutralizers <italic>in vitro</italic> and <italic>in vivo</italic>. Significantly, neutralizing nanobodies showed high epitopic diversity, originating from at least eight different epitope clusters. The vast majority of these V<sub>h</sub>Hs - including NTD and S2 V<sub>h</sub>Hs - remained potent <italic>in vitro</italic> neutralizers against the Alpha, Beta, Gamma, Delta and Kappa variants as well. A sample of <italic>in vitro</italic> neutralizing nanobodies, representing RBD-, NTD- and S2-specific V<sub>h</sub>Hs, were also shown to be efficacious <italic>in vivo</italic> neutralizers as single V<sub>h</sub>H-Fcs or as paired combinations of V<sub>h</sub>H-Fcs that targeted RBD and NTD, with some capable of complete viral clearance from hamster lungs. These results also confirm the strong positive correlation between the <italic>in vitro</italic> and <italic>in vivo</italic> neutralization data and indicate that the remaining <italic>in vitro</italic> neutralizers should also be <italic>in vivo</italic> neutralizers. Moreover, given the broad cross-reactivity and cross-neutralization profiles of many of these nanobodies, it is reasonable to expect these pan-reactive antibodies will also effectively neutralize currently untested and emerging VoCs, e.g., Omicron, and SARS-related viruses.</p>
<p id="P34">The VHH-72 benchmark nanobody, a modified, enhanced V<sub>h</sub>H-Fc version of which is currently being developed for COVID-19 therapy, has the advantage of being broadly neutralizing and binding to a highly conserved cryptic epitope in the RBD region which is difficult to access with conventional mAbs <sup>
<xref ref-type="bibr" rid="R29">29</xref>, <xref ref-type="bibr" rid="R39">39</xref>
</sup>. Here we have identified five VHH-72-like nanobodies (1d, 07, 12, 20, MRed04) that map to the same epitope as VHH-72 and demonstrate similar cross-reactivity and cross-neutralization profiles in the V<sub>h</sub>H-Fc format. In monomeric formats, however, the V<sub>h</sub>Hs significantly outperform VHH-72, but whether they would do the same against the enhanced version of VHH-72 remains to be seen. A similar broad cross-reactivity profile to VHH-72 was seen with two other neutralizing nanobodies (11, SR01) that by HDX/MS experiments map to different but well-conserved epitopes, indicating that these nanobodies may similarly bind to cryptic epitopes conserved across variants. The doubly pan-specific SR01/1d cocktail completely cleared hamsters of viral burden, making for a promising broad-spectrum combination therapeutic.</p>
<p id="P35">With an abundance of neutralizing nanobodies on hand, many possibilities exist for designing optimized multimeric/multi-paratopic therapeutic agents. This is implicitly evident from our epitope binning experiments performed against several SARS-CoV-2 variants (<xref ref-type="supplementary-material" rid="SD1">Fig. S16C</xref>), albeit they exemplified a fraction of potential possibilities. A recent study showed that the neutralization capability of a nanobody significantly increased when fused to a second, non-neutralizing nanobody in a bi-paratopic format <sup>
<xref ref-type="bibr" rid="R43">43</xref>, <xref ref-type="bibr" rid="R74">74</xref>
</sup>. Thus, the pool of V<sub>h</sub>Hs can be expanded to include the entire panel of neutralizing and non-neutralizing nanobodies in the current study, leading to a further exponential increase of multimer possibilities. Including the same or similar (same epitope bin) nanobodies in a multimer construct is plausible given the trimeric nature of the spike glycoprotein and its repetitive presentation on the surface of the virus which should accommodate avid inter-protomer, intra-spike, and/or inter-spike binding events. This is supported by the current data showing increased <italic>in vitro</italic> neutralization potency of nanobodies with homodimerization. CryoEM and X-ray crystallography structures of nanobody-spike glycoprotein complexes would reveal the relative positioning of nanobodies on the surface of the spike glycoprotein and could be used as a guide for designing highly effective and broad-spectrum therapeutic multimers. A comprehensive, high through-put campaign involving small scale expression of multimers followed by <italic>in vitro</italic> screening for broad neutralization can also be envisaged.</p>
<p id="P36">In summary, the nanobodies described here provide ample opportunities to develop broad-spectrum COVID-19 prophylactic/therapeutics of good manufacturability and efficacy. They can be complemented with nanobodies described in the literature for specified performance, although such alternatives would be lacking in the case of our unprecedented NTD- and S2-specific nanobodies. The ability to aerosolize our V<sub>h</sub>Hs provides the option of a cost-effective, patient-friendly, direct and effective delivery of therapeutic nanobodies to the nasal and lung epithelia by inhalation <sup>
<xref ref-type="bibr" rid="R40">40</xref>, <xref ref-type="bibr" rid="R41">41</xref>, <xref ref-type="bibr" rid="R50">50</xref>–<xref ref-type="bibr" rid="R52">52</xref>, <xref ref-type="bibr" rid="R75">75</xref>
</sup>. The nanobodies can additionally be utilized to develop cost-effective, highly sensitive detection/ diagnosis systems of desired cross-reactivity specifications. Epitope type diversity further provides the flexibility of virus detection/diagnosis under native and/or denaturing conditions.</p>
</sec>
<sec id="S12" sec-type="materials | methods">
<label>4</label>
<title>Materials and Methods</title>
<sec id="S13">
<label>4.1</label>
<title>Recombinant antigens and ACE2</title>
<p id="P37">Purified recombinant spike and ACE2 proteins used in the current study are described in <xref ref-type="supplementary-material" rid="SD2">Table S1</xref>. They were either purchased or produced in-house as described (<xref ref-type="supplementary-material" rid="SD2">Table S1</xref>) (<sup>
<xref ref-type="bibr" rid="R76">76</xref>–<xref ref-type="bibr" rid="R80">80</xref>
</sup>). Proteins were purified using standard immobilized metal-ion affinity chromatography or protein A affinity chromatography.</p>
</sec>
<sec id="S14">
<label>4.2</label>
<title>Antigen validation</title>
<sec id="S15">
<label>a)</label>
<title>Binding to cognate human angiotensin converting enzyme (ACE2) receptor</title>
<p id="P38">ELISA was performed to determine if spike glycoprotein fragments (Wuhan) were able to bind to human ACE2 when passively adsorbed (S, S1, RBD and S2) or directionally captured (S1, RBD) on microtiter wells. For passive adsorption, wells of NUNC® Immulon 4 HBX microtiter plates (Thermo Fisher, Ottawa, Canada, Cat#3855) were coated with 50 ng of SARS-CoV-2 spike proteins (S, S1, S2, RBD) in 100 μL of phosphate-buffered saline (PBS) overnight at 4°C. Following removal of protein solutions and three washes with PBST (PBS supplemented with 0.05% [v/v] Tween 20), wells were blocked with PBSC (1% [w/v] casein [Sigma, Oakville, Canada, Cat#E3414] in PBS) at room temperature for 1 h. For capturing, <italic>in vivo</italic> biotinylated fragments harboring the AviTag™ (AviTag-S1, AviTag-RBD) were diluted in PBS and added at 50 ng/well (100 μL) to pre-blocked Streptavidin Coated High Capacity Strip wells (Thermo Fisher, Cat#15501). After 1 h incubation at room temperature, wells were washed five times with PBST and incubated for an additional hour with 100 μL/well of 2-fold serially diluted ACE2-Fc (human ACE2 fused to human IgG1 Fc; ACROBiosystems, Newark, DE, Cat#AC2-H5257) in PBSTC (PBS/0.2% casein/0.1% Tween 20). Wells were washed five times and incubated for 1 h with 1 μg/mL HRP-conjugated goat anti-human IgG (Sigma, Cat#A0170). Finally, wells were washed 10 times and incubated with 100 μL peroxidase substrate solution (SeraCare, Milford, M, Cat#50-76-00) at room temperature for 15 min. Reactions were stopped by adding 50 μL 1 M H2SO4 to wells, and absorbance were subsequently measured at 450 nm using a Multiskan™ FC photometer (Thermo Fisher).</p>
</sec>
<sec id="S16">
<label>b)</label>
<title>Binding to cognate anti-spike glycoprotein polyclonal antibody</title>
<p id="P39">The four spike glycoprotein antigens were passively adsorbed as described above. After blocking with PBSC, wells were emptied, washed five times with PBST and incubated at room temperature for 1 h with 100 μL of 1 μg/mL anti-SARS-CoV-2 spike rabbit polyclonal antibody (Sino Biological, Beijing, China, Cat#40589-T62) in PBSCT. Following 10 washes with PBST, wells were incubated with 100 μL 1/2500 dilution (320 ng/mL) of goat anti-rabbit:HRP (Jackson ImmunoResearch, West Grove, PA, Cat#111-035-144) in PBSCT for 1 h at room temperature. After 1 h incubation and final five washes with PBST, the peroxidase activity was determined as described above.</p>
</sec>
</sec>
<sec id="S17">
<label>4.3</label>
<title>Llama immunization and serum analyses</title>
<sec id="S18">
<label>a)</label>
<title>Llama immunization</title>
<p id="P40">Immunizations were performed at Cedarlane Laboratories (Burlington, Canada) essentially as described <sup>
<xref ref-type="bibr" rid="R81">81</xref>, <xref ref-type="bibr" rid="R82">82</xref>
</sup>, using SARS-CoV-2 Wuhan spike glycoprotein fragments. Briefly, for priming, both llamas (Green and Red) were injected with 100 μg of S in 500 μL PBS combined with 500 μL of Freund’s Complete Adjuvant. For the three subsequent boosts (days 7, 14, 21), Green was injected with 70 μg of RBD (ACROBiosystems, Cat#SPD-S52H6) whereas Red received 100 μg of S <sup>
<xref ref-type="bibr" rid="R78">78</xref>
</sup> at day 7 and 50 μg of S on days 14 and 21 all with Freund’s Incomplete Adjuvant. Experiments involving animals were conducted using protocols approved by the National Research Council Canada Animal Care Committee and in accordance with the guidelines set out in the OMAFRA Animals for Research Act, R.S.O. 1990, c. A.22.</p>
</sec>
<sec id="S19">
<label>b)</label>
<title>Serum ELISA</title>
<p id="P41">Llama sera were tested for antigen-specific immune response by ELISA essentially as described <sup>
<xref ref-type="bibr" rid="R82">82</xref>, <xref ref-type="bibr" rid="R83">83</xref>
</sup>. Briefly, dilutions of sera in PBST were added to wells pre-coated with S, S1, S2 or RBD. Negative antigen control wells were pre-coated with casein (100 μL of 1%) or dipeptidase 1, DPEP1 (50 ng/well; Sino Biological, Cat#13543-H08H). Following 1 h incubation at room temperature, wells were washed 10 times with PBST and incubated with HRP-conjugated polyclonal goat anti-llama IgG heavy and light chain antibody (Bethyl Laboratories, Montgomery, TX, Cat#A160-100P) for 1 h at room temperature. After 10 washes, the peroxidase activity was determined as described in <bold>
<italic>4.2a</italic>
</bold>.</p>
</sec>
<sec id="S20">
<label>c)</label>
<title>Serum surrogate neutralization assay by flow cytometry</title>
<p id="P42">SARS-CoV-2 S was chemically biotinylated using EZ-Link™ NHS-LC-LC-Biotin following manufacturer instructions (Thermo Fisher, Cat#21343). Vero E6 cells (ATCC, Cat#CRL-1586) were maintained according to ATCC protocols. Briefly, cells were grown to confluency in DMEM medium (Thermo Fisher, Cat#11965084) supplemented with 10% (w/v) heat inactivated fetal bovine serum (FBS; (Thermo Fisher, Cat#10438034) and 2 mM Glutamax (Thermo Fisher, Cat#35050061) at 37°C in a humidified 5% CO<sub>2</sub> atmosphere in T75 flasks. For flow cytometry experiments, cells were harvested by Accutase (Thermo Fisher, Cat#A1110501) treatment, washed once by centrifugation with PBS, and resuspended at 1 × 10<sup>6</sup> cells/mL in PBSB (PBS containing 1% [w/v] BSA and 0.05% [v/v] sodium azide [Sigma, Cat#S2002]). Cells were kept on ice until use. To determine the presence of antibodies that block the binding of S to ACE2 (surrogate for neutralization) in the immune sera of llamas, 400 ng of chemically biotinylated SARS-CoV-2 S was mixed with 1 × 10<sup>5</sup> Vero E6 cells in the presence of 2-fold dilutions of sera (pre immune, day 21 and day 28 sera) in a final volume of 150 μL. Following 1 h of incubation on ice, cells were washed twice with PBSB by centrifugation for 5 min at 1200 rpm and then incubated for an additional hour with 50 μL of Streptavidin, R-Phycoerythrin Conjugate (SAPE, Thermo Fisher, Cat#S866) at 250 ng/mL diluted in PBSB. After a final wash, cells were resuspended in 100 μL PBSB and data were acquired on a CytoFLEX S flow cytometer (Beckman Coulter, Brea, CA) and analyzed by FlowJo software (FlowJo LLC, v10.6.2, Ashland, OR). Percent inhibition (neutralization) was calculated according to the following formula: <disp-formula id="FD1">
<mml:math id="M1">
<mml:mrow>
<mml:mi>%</mml:mi>
<mml:mtext> inhibition</mml:mtext>
<mml:mo>=</mml:mo>
<mml:mn>100</mml:mn>
<mml:mo>×</mml:mo>
<mml:mo stretchy="false">[</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>F</mml:mi>
<mml:mi>n</mml:mi>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>F</mml:mi>
<mml:mrow>
<mml:mi>min</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>/</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>F</mml:mi>
<mml:mrow>
<mml:mi>max</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>F</mml:mi>
<mml:mrow>
<mml:mi>min</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">]</mml:mo>
</mml:mrow>
</mml:math>
</disp-formula>
</p>
<p id="P43">Where,</p>
<p id="P44">
<italic>F</italic>
<sub>n</sub> is the measured fluorescence at any given competitor serum dilution</p>
<p id="P45">
<italic>F</italic>
<sub>min</sub> is the background fluorescence measured in the presence of cells and SAPE only</p>
<p id="P46">
<italic>F</italic>
<sub>max</sub> is the maximum fluorescence measured in the absence of competitor serum</p>
</sec>
</sec>
<sec id="S21">
<label>4.4</label>
<title>Phage display library construction, selection and screening</title>
<sec id="S22">
<label>a)</label>
<title>Phage display library construction</title>
<p id="P47">On day 28, 100 mL of blood from each of the two llamas was drawn and peripheral blood mononuclear cells (PBMCs) were purified by ficoll gradient at Cedarlane Laboratories. Two independent phage-displayed V<sub>h</sub>/V<sub>h</sub>H libraries were constructed from ~5 × 10<sup>7</sup> PBMCs as described previously <sup>
<xref ref-type="bibr" rid="R81">81</xref>, <xref ref-type="bibr" rid="R82">82</xref>, <xref ref-type="bibr" rid="R84">84</xref>
</sup>. Briefly, total RNA was extracted from PBMCs using TRIzol™ Plus RNA Purification Kit (Thermo Fisher, Cat#12183555) following the manufacturer’s instructions and used to reverse transcribe cDNA with SuperScript™ IV VILO™ Master Mix supplemented with random hexamer (Thermo Fisher, Cat#SO142) and oligo (dT) (Thermo Fisher, Cat#AM5730G) primers. V<sub>h</sub>/V<sub>h</sub>H genes were amplified using semi-nested PCR and cloned into the phagemid vector pMED1, followed by transformation of <italic>E. coli</italic> TG1 (Lucigen, Middleton, WI, Cat#60502-02) to construct two libraries with sizes of 1 × 10<sup>7</sup> and 2 × 10<sup>7</sup> independent transformants for Green and Red, respectively. Both libraries showed an insert rate of ~95% as verified by DNA sequencing. Phage particles displaying the V<sub>h</sub>Hs were rescued from <italic>E. coli</italic> cell libraries using M13K07 helper phage (New England Biolabs, Whitby, Canada, Cat#N0315S) as described in <sup>
<xref ref-type="bibr" rid="R81">81</xref>
</sup> and used for selection experiments described below.</p>
</sec>
<sec id="S23">
<label>b)</label>
<title>Library selection and screening</title>
<p id="P48">Library panning and screening were performed essentially as described <sup>
<xref ref-type="bibr" rid="R81">81</xref>, <xref ref-type="bibr" rid="R82">82</xref>, <xref ref-type="bibr" rid="R85">85</xref>
</sup>, using SARS-CoV-2 Wuhan spike glycoprotein fragments as target antigens. Library selections were performed on microtiter wells under six different phage binding/elution conditions designated P1 – P6. Briefly, for the phage binding step, library phages were diluted at 1 × 10<sup>11</sup> colony-forming units (CFU)/mL in PBSBT [PBS supplemented with 1% BSA and 0.05% Tween 20] and incubated in antigen-coated microtiter wells for 2 h at 4°C. For P1 – P4, phages were added to wells with passively-adsorbed S (10 μg/well; P1), passively-adsorbed S2 (10 μg/well; P2), streptavidin-captured biotinylated S1 (0.5 μg/well; P3) and streptavidin-captured biotinylated RBD (0.5 μg/well; P4). For P5, phages were pre-absorbed on passively-adsorbed RBD wells (10 μg/well) for 1 h at 4°C and then the unbound phage in the solution was transferred to wells with streptavidin-captured biotinylated S1 (0.5 μg/well) in the presence of non-biotinylated RBD competitor in solution (10 μg/well). Following the binding stage (P1 – P5), wells were washed 10 times with PBST and bound phages were eluted by treatment with 100 mM glycine, pH 2.2, for 10 min at room temperature, followed by immediate neutralization of phages with 2 M Tris. Similar to P4, in P6, phages were bound on streptavidin-captured biotinylated RBD but elution of bound phages were carried out competitively with 50 nM human ACE2-Fc following the washing step. For all pannings, a small aliquot of eluted phage was used to determine the titer on LB-agar/ampicillin plates and the remaining phage were used for subsequent amplification in <italic>E.coli</italic> TG1 strain <sup>
<xref ref-type="bibr" rid="R81">81</xref>
</sup>. The amplified phages were used as input for the next round of selection as described above.</p>
<p id="P49">After two rounds of selection, 16 (Green) or 12 (Red) colonies from each of the P1 – P6 selections were screened for antigen binding by monoclonal phage ELISA against S, S1, S2 and RBD. Briefly, individual colonies from eluted-phage titer plates were grown in 96 deep well plates in 0.5 mL 2YT media/100 μg/mL-carbenicillin/1% (w/v) glucose at 37°C and 250 rpm to an OD600 of 0.5. Then, 10<sup>10</sup> CFU M13K07 helper phage was added to each well and incubation continued for another 30 min under the same conditions. Cells were subsequently pelleted by centrifugation, the supernatant was discarded and the bacterial pellets were resuspended in 500 μL 2YT/100 μg/mL carbenicillin/50 μg/mL kanamycin and incubated overnight at 28°C. Next day, phage supernatants were recovered by centrifugation, diluted 3-fold in PBSTC and used in subsequent screening assays by ELISA. To this end, antigens were coated onto microtiter wells at 50 ng/well overnight at 4°C. Next day, plates were blocked with PBSC, washed five times with PBSTC, and 100 μL of phage supernatants prepared above were added to wells, followed by incubation for 1 h at room temperature in an orbital shaking platform. After 10 washes, binding of phages was detected by adding 100 μL/well of anti-M13:HRP (Santa Cruz Biotechnology, Santa Cruz, CA, Cat#SC-53004HRP) at 40 ng/mL in PBSTC and incubating as above. After 10 washes, the peroxidase activity was determined as described in <bold>
<italic>4.2a</italic>
</bold>. After monoclonal phage ELISA confirmed the library panning was successful,, a total of ≈1200 clones (≈100 clones per panning strategy; ≈600 clones per library) were subjected to colony-PCR and DNA sequencing, resulting in the identification of 26 (Green) and 11 (Red) V<sub>h</sub>Hs.</p>
</sec>
</sec>
<sec id="S24">
<label>4.5</label>
<title>Expression and purification of V<sub>h</sub>Hs and V<sub>h</sub>H-Fcs</title>
<sec id="S25">
<label>a)</label>
<title>Expression and validation of V<sub>h</sub>Hs</title>
<p id="P50">Positive V<sub>h</sub>Hs were cloned into a modified pET expression vector (pMRo.BAP.H6) for their production in BL21(DE3) <italic>E.coli</italic> as monomeric soluble protein <sup>
<xref ref-type="bibr" rid="R84">84</xref>
</sup>. For the VHH-72 benchmark <sup>
<xref ref-type="bibr" rid="R29">29</xref>
</sup>, the sequence of the V<sub>h</sub>H was synthesized as a GeneBlock (Integrated DNA Technologies, Coralville, IA) flanked by SfiI sites for cloning into pMRo.BAP.H6. Briefly, individual colonies were cultured overnight in 10 mL LB supplemented with 50 μg/mL of kanamycin (LB/Kan) at 37°C and 250 rpm. After 16 h, cultures were added to 250 mL LB/Kan and grown to an OD600 of 0.6. Expression of V<sub>h</sub>Hs was induced with 10 μM of IPTG (isopropyl β-D-1-thiogalactopyranoside) overnight at 28°C and 250 rpm. Next day, bacterial pellets were harvested by centrifugation at 6,000 rpm for 15 min at 4°C, V<sub>h</sub>Hs were extracted by sonication and purified by IMAC as described <sup>
<xref ref-type="bibr" rid="R84">84</xref>
</sup>. Protein purity was evaluated by SDS-PAGE using 4-20% Mini-PROTEAN® TGX Stain-Free™ Gels (BioRad, Hercules, CA, Cat#17000435). In addition, for ELISA (<italic>see</italic> below), V<sub>h</sub>Hs were enzymatically biotinylated in their BAP tag by incubating 1 mg of purified V<sub>h</sub>Hs with 10 μM of ATP (Alfa Aesar, Haverhill, MA, Cat#CAAAJ61125-09), 100 μM of D-(+)-biotin (VWR, Mississauga, Canada; Cat#97061-446) and bacterial cell extract overexpressing <italic>E.coli</italic> BirA as described <sup>
<xref ref-type="bibr" rid="R81">81</xref>
</sup>. V<sub>h</sub>Hs were validated for binding by soluble ELISA against spike glycoprotein fragments (S, S1, RBD, NTD, S2). Briefly, microtiter well plates were coated with 50 ng/well SARS-CoV-2 spike glycoprotein fragments in 100 μL PBS overnight at 4°C. Plates were blocked with PBSC for 1 h at room temperature, then washed five times with PBST and incubated with increasing concentrations of biotinylated V<sub>h</sub>Hs. After 1 h incubation, plates were washed 10 times with PBST and binding of V<sub>h</sub>Hs was probed using HRP-streptavidin (Jackson ImmunoResearch, Cat#016-030-084). Finally, plates were washed 10 times with PBST and peroxidase activity was determined as described in <bold>
<italic>4.2a</italic>
</bold>.</p>
</sec>
<sec id="S26">
<label>b)</label>
<title>Production of V<sub>h</sub>Hs in mammalian cells in fusion with human IgG1 Fc (V<sub>h</sub>H-Fcs)</title>
<p id="P51">Codon-optimized genes for bivalent V<sub>h</sub>H-Fcs were synthesized and cloned into pTT5 (GenScript; Piscataway, NJ. For VHH-72 V<sub>h</sub>H-Fc, <sup>
<xref ref-type="bibr" rid="R29">29</xref>
</sup> the sequence of the V<sub>h</sub>H was synthetized as GeneBlock (Integrated DNA Technologies) flanked by NarI/HindIII for cloning into pTT5. V<sub>h</sub>H-Fcs were produced by transient transfection of HEK293-6E cells followed by protein A affinity chromatography as previously described <sup>
<xref ref-type="bibr" rid="R84">84</xref>
</sup>. Proteins were buffer exchanged using Amicon® Ultra-15 Centrifugal Filter Units (Millipore-Sigma, Oakville, Canada, Cat#UFC905024) with PBS, pH 7.4. Protein purity was evaluated by SDS-PAGE using 4-20% Mini-PROTEAN® TGX Stain-Free™ Gels (BioRad; Cat#17000435).</p>
</sec>
</sec>
<sec id="S27">
<label>4.6</label>
<title>Affinity and specificity assays</title>
<sec id="S28">
<label>a)</label>
<title>Cross-reactivity assays by ELISA</title>
<p id="P52">Recombinant coronavirus spike glycoproteins S (<xref ref-type="supplementary-material" rid="SD2">Table S1</xref>) were coated overnight onto NUNC® Immulon 4 HBX microtiter plates (Thermo Fisher) at 50 ng/well in 100 μL of PBS, pH 7.4. The next day, plates were blocked with 200 μL PBSC for 1 h at room temperature, then washed five times with PBST and incubated at room temperature for 1 h on rocking platform at 80 rpm with 1 μg/mL V<sub>h</sub>H-Fc diluted in PBSTC. Plates were washed five times with PBSTC and binding of V<sub>h</sub>H-Fcs was detected using 1 μg/mL HRP-conjugated goat anti-human IgG. Finally plates were washed five times and peroxidase (HRP) activity was measured as described in <bold>
<italic>4.2a</italic>
</bold>.</p>
</sec>
<sec id="S29">
<label>b)</label>
<title>Affinity/specificity determination of V<sub>h</sub>Hs against SARS-CoV spike (S), SARS-CoV-2 spike (S) and SARS-CoV-2 spike fragments by surface plasmon resonance (SPR)</title>
<p id="P53">Standard SPR techniques were used for binding studies. All SPR assays were performed on a Biacore T200 instrument (Cytiva, Vancouver, Canada) at 25°C with HBS-EP running buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% Tween 20, pH 7.4) and CM5 sensor chips (Cytiva). Prior to SPR analyses all analytes in flow (V<sub>h</sub>Hs, ACE2 receptor) were purified by size exclusion chromatography (SEC) on a Superdex 75™ Increase 10/300 GL column (Cytiva) in HBS-EP buffer at a flow rate of 0.8 mL/min to obtain monomeric proteins. SARS-CoV spike glycoprotein (S), SARS-CoV-2 spike glycoprotein (S) <sup>
<xref ref-type="bibr" rid="R78">78</xref>
</sup> and various SARS-CoV-2 spike glycoprotein fragments were immobilized on CM5 sensor chips through standard amine coupling (10 mM acetate buffer, pH 4.0, Cytiva). On the first sensor chip, 1983 response units (RUs) of SARS-CoV spike (SinoBiological, Cat#40634-V08B), 843 RUs of SARS-CoV-2 RBD/SD1 fused to human Fc (RBD/SD1-Fc) and 972 RUs of EGFR (Genscript, Piscataway, NJ, Cat# Z03194, as an irrelevant control surface) were immobilized. On a second sensor chip, 2346 RUs of SARS-CoV-2 S, 1141 RUs of SARS-CoV-2 S1 subunit and 1028 RUs of SARS-CoV-2 S2 subunit were immobilized. A third sensor chip contained 489 RUs of RBD_short <sup>
<xref ref-type="bibr" rid="R78">78</xref>
</sup>. The theoretical maximum binding response for V<sub>h</sub>Hs binding to these surfaces ranged from 224 – 262 RUs. An ethanolamine blocked surface on each sensor chip served as a reference. Single cycle kinetics was used to determine V<sub>h</sub>H and ACE2 binding kinetics and affinities. V<sub>h</sub>Hs at various concentration ranges (from 0.25 – 4 nM to 125 – 2000 nM) were flowed over all surfaces at a flow rate of 40 μL/min with 180 s of contact time and 600 s of dissociation time. Surfaces were regenerated with a 12 s pulse of 10 mM glycine, pH 1.5, at a flow rate of 100 μL/min. Injection of EGFR-specific V<sub>h</sub>H NRCsdAb022 <sup>
<xref ref-type="bibr" rid="R84">84</xref>
</sup> served as a negative control for the SARS-CoV and SARS-CoV-2 surfaces and as a positive control for the EGFR surface. The ACE2 affinity was determined using similar conditions by flowing a range of monomeric ACE2 concentrations (31.3 – 500 nM). SARS-CoV-2 spike glycoproteins from Alpha and Beta variants were also tested by SPR and amine coupled using the conditions described above. All affinities were calculated by fitting reference flow cell-subtracted data to a 1:1 interaction model using BIAevaluation Software v3.0 (Cytiva).</p>
<p id="P54">For V<sub>h</sub>H 12 and MRed05, V<sub>h</sub>H-Fc formats were used in SPR experiments. Approximately 200 RUs of V<sub>h</sub>H-Fcs (2 μg/mL) were captured on goat anti-human IgG surfaces (4000 RUs, Jackson ImmunoResearch, Cat#109-005-098) at a flow rate of 10 μL/min for 30 s. A range of SEC-purified RBD fragments (<xref ref-type="supplementary-material" rid="SD2">Table S1</xref>; Wuhan <sup>
<xref ref-type="bibr" rid="R78">78</xref>
</sup>, Alpha and Beta) at 0.62 – 10 nM were flowed over the captured V<sub>h</sub>H-Fc at a flow rate of 40 μL/min with 180 s of contact time and 300 s of dissociation. Surfaces were regenerated with a 120 s pulse of 10 mM glycine, pH 1.5, at a flow rate of 50 μL/min. Affinities were calculated from reference flow cell subtracted sensorgrams as described above.</p>
</sec>
<sec id="S30">
<label>c)</label>
<title>Domain specificity determination of V<sub>h</sub>Hs by ELISA</title>
<p id="P55">V<sub>h</sub>Hs which bound to S1 subunit but not to the RBD domain in SPR assays were further examined by ELISA to determine if they were binding to the NTD domain of S1. Briefly, S, S1, NTD and RBD were coated onto NUNC® Immulon 4 HBX microtiter plates at 100 ng/well in 100 μL PBS, pH 7.4. Next day, plates were blocked with 200 μL PBSC for 1 h at room temperature, then washed five times with PBST and incubated with fixed (13 nM) or decreasing concentrations of V<sub>h</sub>H-Fcs diluted in PBSTC. After 1 h, plates were washed 10 times with PBSTC and binding of V<sub>h</sub>H-Fc fusions was detected by incubating wells with 100 μL of 1 μg/mL HRP-conjugated goat anti-human IgG. Finally, plates were washed 10 times with PBST and peroxidase activity was determined as described in <bold>
<italic>4.2a</italic>
</bold>. <italic>EC</italic>
<sub>50</sub>s for the binding of V<sub>h</sub>H-Fcs to S and S fragments were obtained from the plot of A450 nm (binding) <italic>vs</italic> V<sub>h</sub>H-Fc concentration.</p>
</sec>
<sec id="S31">
<label>d)</label>
<title>Cell binding assays by flow cytometry</title>
<p id="P56">CHO<sup>55E1</sup>™ cells expressing full-length (including transmembrane and C-terminal domains) SARS-CoV-2 Wuhan S (CHO-SPK) under control of the cumate-inducible CR5 promoter were generated by methionine sulfoximine (MSX) selection of plasmid-transfected cells, as described <sup>
<xref ref-type="bibr" rid="R86">86</xref>
</sup>. Cells were grown in BalanCD™ CHO Growth A medium (Irvine Scientific, Santa Ana, CA) supplemented with 50 μM methionine sulfoximine (MSX) at 120 rpm and 37°C in a humidified 5% CO<sub>2</sub> atmosphere. Expression of S was induced by adding cumate at 2 μg/mL for 48 h at 32°C. For flow cytometry experiments, cells were harvested by centrifugation and resuspended at 1 × 10<sup>6</sup> cells/mL in PBSB. Cells were kept on ice until use. Serially, three-fold dilutions of V<sub>h</sub>H-Fcs were prepared in V-Bottom 96-well microtiter plates (Globe Scientific, Mahwah, NJ, Cat# 120130) and mixed with 50 μL of CHO-SPK cells. Plates were incubated for 1 h on ice, washed twice with PBSB by centrifugation for 5 min at 1200 rpm and then incubated for an additional hour with 50 μL of R-Phycoerythrin AffiniPure F(ab’)<sub>
<bold>2</bold>
</sub> Fragment Goat Anti-Human IgG (Jackson ImmunoResearch, Cat#109-116-170) at 250 ng/mL diluted in PBSB. After a final wash, cells were resuspended in 100 μL PBSB and data were acquired on a Beckman Coulter CytoFlex S and analyzed by FlowJo™ (FlowJo LLC, v10.6.2). <italic>EC<sub>50</sub>s</italic> for the binding of V<sub>h</sub>H-Fcs to CHO-SPK cells were obtained from the plot of MFI (Mean Fluorescent Intensity) <italic>vs</italic> V<sub>h</sub>H-Fc concentration.</p>
</sec>
</sec>
<sec id="S32">
<label>4.7</label>
<title>Stability assays</title>
<sec id="S33">
<label>a)</label>
<title>Determination of aggregation resistance by SEC</title>
<p id="P57">Purified V<sub>h</sub>Hs were subjected to SEC to validate their aggregation resistance. Briefly, 2 mg of each affinity purified V<sub>h</sub>H was injected into Superdex™ 75 10/300 GL column (Cytiva) connected to an AKTA FPLC protein purification system (Cytiva) as previously described <sup>
<xref ref-type="bibr" rid="R87">87</xref>
</sup>. PBS was used as the running buffer at 0.8 mL/min. Fractions corresponding to the monomeric peak were pooled and stored at 4°C until use.</p>
</sec>
<sec id="S34">
<label>b)</label>
<title>Thermostability determinations by circular dichroism</title>
<p id="P58">To determine thermostability, V<sub>h</sub>H T<sub>m</sub>s were measured by circular dichroism as previously described <sup>
<xref ref-type="bibr" rid="R87">87</xref>
</sup>. Ellipticity of V<sub>h</sub>Hs were determined at 200 μg/mL V<sub>h</sub>H concentrations and 205 nm wavelength in 100 mM sodium phosphate buffer, pH 7.4. Ellipticity measurements were normalized to percentage scale and <italic>T</italic>
<sub>m</sub>s were determined from plot of % folded <italic>vs</italic> temperature and fitting the data to a Boltzmann distribution.</p>
</sec>
<sec id="S35">
<label>c)</label>
<title>Isothermal chemical denaturation (ICD)</title>
<p id="P59">All ICD experiments were performed with the automated Hunky system (Unchained Labs, Pleasanton, CA), using Hunky Client software (v1.2). V<sub>h</sub>Hs were prepared in PBS buffer, pH 7.2 (Teknova, Hollister, CA, Cat#P0191), and diluted by Hunky automation to 20 μg/mL. They were denatured using a linear dilution gradient of 0 – 5.52 M guanidine-HCl (Sigma, Cat#G3272) and incubated for 2 h at 25°C. Samples were subjected to LED excitation at 280 nm, and emission spectra of the V<sub>h</sub>H were captured by a CCD spectrometer from 300 – 720 nm. The Hunky Analysis v1.2 Software automatically plotted the fluorescence intensity against denaturant concentration, and generated a data fit curve for two-state transitions of each V<sub>h</sub>H. All samples were analyzed by the Hunky software using the Barycentric Mean (BCM) except for 05 (348/342 nm ratio), 06 (single 348 nm) and 07 (wavelength diff. 348-420 nm) to determine Δ<italic>G</italic>
<sup>0</sup> (kJ/mol), <italic>C</italic>
<sub>m</sub> (M) and <italic>m</italic> (kJ/M*mol). The fraction denatured was automatically plotted against denaturant concentration to confirm the two-state model. The denatured-induced unfolding of V<sub>h</sub>Hs was considered to be reversible based on their small size as shown to be the case for small proteins and numerous times for V<sub>h</sub>Hs <sup>
<xref ref-type="bibr" rid="R56">56</xref>–<xref ref-type="bibr" rid="R59">59</xref>, <xref ref-type="bibr" rid="R88">88</xref>, <xref ref-type="bibr" rid="R89">89</xref>
</sup>.</p>
</sec>
<sec id="S36">
<label>d)</label>
<title>Serum stability</title>
<p id="P60">Three female Syrian hamsters were injected intraperitoneally (IP) with 1 mg of 1d or VHH-72 V<sub>h</sub>H-Fc diluted in 200 μL PBS. Animal were bled on day 0, 1 and 4 post injection and their sera were subjected to ELISA to detect their V<sub>h</sub>H-Fc levels. Briefly, sera were diluted 1/6000, in order to give final A450nm readings of ≤ 1 in 15 min, and incubated 1 h at room temperature in wells coated with SARS-CoV-2 Wuhan S <sup>
<xref ref-type="bibr" rid="R78">78</xref>
</sup>. The binding of V<sub>h</sub>H-Fcs within the sera was detected using 1 μg/mL goat anti-human IgG Fc, HRP-conjugated (Thermo Fisher, Cat#A18829). Plates were washed five times with PBST and peroxidase (HRP) activity was detected as described in <bold>4.2a</bold>. The levels of 1d and VHH-72 V<sub>h</sub>H-Fcs in sera were quantified by interpolating obtained A<sub>450nm</sub> readings against A<sub>450nm</sub> <italic>vs</italic> [V<sub>h</sub>H-Fc] standard curves generated with purified 1d and VHH-72 V<sub>h</sub>H-Fcs, respectively.</p>
</sec>
<sec id="S37">
<label>e)</label>
<title>Aerosolization studies</title>
<p id="P61">Prior to aerosolization, 4 mg of each V<sub>h</sub>H were purified by SEC using a Superdex 75™ 10/300 GL column (Cytiva) and PBS as running buffer, as described above. Protein fractions corresponding to the chromatogram’s monomeric peak were pooled, quantified and its concentration adjusted to 0.5 mg/mL. One mL of each V<sub>h</sub>H was subsequently aerosolized at room temperature with a portable mesh nebulizer (AeroNeb Solo, Aerogen, Galway, Ireland), which produces 3.4-μm particles. Aerosolized V<sub>h</sub>Hs were collected into 15 mL round-bottom polypropylene test tubes (VWR, Cat#C352059) for 5 min to allow condensation and were subsequently quantified and kept at 4°C until use. Then 200 μL aliquots of pre- and post- aerosolized V<sub>h</sub>Hs were subjected to SEC to obtain chromatogram profiles. Additionally, condensed V<sub>h</sub>Hs were closely monitored for the formation of any visible aggregates, and in cases where aggregate formation were observed, they were removed by centrifugation prior to concentration determination, SEC analysis and ELISA. % soluble aggregate was determined as the proportion of a V<sub>h</sub>H that gave elution volumes (<italic>V</italic>
<sub>e</sub>s) smaller than that of the monomeric V<sub>h</sub>H fraction. % recovery was determined as the proportion of a V<sub>h</sub>H that remained monomer following aerosolization.</p>
<p id="P62">To assess the effect of aerosolization on functionality of V<sub>h</sub>Hs, the activities of post-aerosolized V<sub>h</sub>Hs were determined by ELISA and compared to those for pre-aerosolized V<sub>h</sub>Hs. To perform ELISA, S1-Fc (ACRO Biosystems, Cat#S1N-C5255) was diluted in PBS to 500 ng/mL, and 100 μL/well were coated overnight at 4°C. Next day, plates were washed with PBST and blocked with 200 μL PBSC for 1 h at room temperature. After five washes with PBST, serial dilutions of the pre- and post- aerosolized V<sub>h</sub>Hs were added to wells and incubated for 1 h at room temperature. Then plates were washed 10 times with PBST and binding of V<sub>h</sub>Hs to S1-Fc was detected with rabbit anti-6xHis Tag antibody HRP Conjugate (Bethyl Laboratories, Cat#A190-114P), diluted at 10 ng/mL in PBST and added at 100 μL/well. Finally, after 1 h incubation at room temperature and final washes with PBST, peroxidase (HRP) activity was determined as described in <bold>
<italic>4.2a</italic>
</bold>.</p>
</sec>
</sec>
<sec id="S38">
<label>4.8</label>
<title>Epitope typing, binning and mapping</title>
<sec id="S39">
<label>a)</label>
<title>Epitope typing by sodium dodecyl sulphate-polyacrylamide gel electrophoresis/western blotting (SDS-PAGE/WB)</title>
<p id="P63">A standard SDS-PAGE/WB was performed to detect the binding of V<sub>h</sub>H-Fcs to nitrocellulose-immobilized, denatured SARS-CoV-2 Wuhan S. Briefly, 10 μg/lane of S was run on 4-20% Mini-PROTEAN® TGX Stain-Free™ Protein Gels (BioRad, Cat#4568081), transferred to nitrocellulose (Sigma, Cat#GE10600002) and blocked with 1% PBSC overnight at 4°C. Then, 0.5-cm nitrocellulose strips containing the denatured S were placed on Mini Incubation Trays (BioRad, Cat#1703902) and incubated with 1 mL of 1 μg/mL V<sub>h</sub>H-Fcs. After 1 h incubation at room temperature, strips were washed 10 times with PBST and the binding of V<sub>h</sub>H-Fcs to denatured S was probed by incubating strips with 1 mL of 100 ng/mL anti-human Ig Fc antibody-peroxidase conjugate (Jackson ImmunoResearch, Cat#016-030-084) at room temperature for 1 h. Finally, strips were washed 10 times with PBST and peroxidase activity was detected using chemiluminescent reagent (SuperSignal West Pico PLUS Chemiluminescent Substrate, Thermo Fisher, Cat#34580). Images of developed strips were acquired on Molecular Imager® Gel Doc™ XR System (BioRad, Cat#1708195EDU).</p>
</sec>
<sec id="S40">
<label>b)</label>
<title>Epitope binning by SPR</title>
<p id="P64">Standard SPR techniques were used for binding studies. All SPR assays were performed on a Biacore T200 instrument (Cytiva) at 25°C with HBS-EP running buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% Tween 20, pH 7.4) and CM5 sensor chips (Cytiva). Prior to SPR analyses all analytes in flow (V<sub>h</sub>Hs, ACE2 receptor) were SEC-purified on a Superdex 75™ Increase 10/300 GL column (Cytiva) in HBS-EP buffer at a flow rate of 0.8 mL/min to obtain monomeric proteins. V<sub>h</sub>H epitope binning was performed by SPR dual injection experiments on the SARS-CoV-2 S surface at a flow rate of 40 μL/min in HBS-EP buffer. Dual injections consisted of injection of V<sub>h</sub>H1 (at 50 – 100 × <italic>K</italic>
<sub>d</sub> concentration) for 150 s, followed by immediate injection of a mixture of V<sub>h</sub>H1 + V<sub>h</sub>H2 (both at 50 – 100 × <italic>K</italic>
<sub>D</sub> concentration) for 150 s. The opposite orientation was also performed (V<sub>h</sub>H2 followed by V<sub>h</sub>H2 + V<sub>h</sub>H1). Surfaces were regenerated using a 12 s pulse of 10 mM glycine, pH 1.5, at a flow rate of 100 μL/min. All pairwise combinations of V<sub>h</sub>Hs were analyzed and distinct or overlapping epitope bins determined.</p>
</sec>
<sec id="S41">
<label>c)</label>
<title>Epitope binning by ELISA</title>
<p id="P65">The pairwise ability of V<sub>h</sub>Hs to bind to their antigen in a sandwich ELISA format was evaluated as described previously <sup>
<xref ref-type="bibr" rid="R85">85</xref>, <xref ref-type="bibr" rid="R90">90</xref>, <xref ref-type="bibr" rid="R91">91</xref>
</sup> and according to the design depicted in <xref ref-type="supplementary-material" rid="SD1">Fig S16B</xref>. Briefly, a matrix of 20 well (row) × 29 well (column) in nine NUNC® Immulon 4 HBX microtiter plates (Thermo Fisher) was coated overnight at 4°C with 4 μg/mL streptavidin (Jackson ImmunoResearch, Cat#016-000-113) in 100 μL PBS, pH 7.4. Wells were blocked with 200 μL PBSC for 1 h at room temperature and then biotinylated V<sub>h</sub>Hs at 10 μg/mL in 100 μL PBSCT were captured in each row (same V<sub>h</sub>H in each row; 20 rows for a total of 20 V<sub>h</sub>Hs) for 1 h at room temperature. Wells were washed 5 times with PBST and incubated with 100 ng/mL of SARS-CoV-2 Wuhan S1 diluted in PBSCT for 1 h. Wells were washed and each column was incubated with the pairing, V<sub>h</sub>H-Fcs/ACE2-Fc at 1 μg/mL used as detector antibodies (same V<sub>h</sub>H-Fc/ACE2-Fc in each column; 29 columns for a total of 28 V<sub>h</sub>H-Fcs and ACE2-Fc). The binding of V<sub>h</sub>H-Fcs/ACE2-Fc to S1 was detected using 100 μL 1 μg/mL HRP-conjugated goat anti-human IgG (Sigma, Cat#A0170). Finally, plates were washed 10 times with PBST and peroxidase (HRP) activity was determined as described in <bold>
<italic>4.2a</italic>
</bold>.</p>
</sec>
<sec id="S42">
<label>d)</label>
<title>Bottom-up hydrogen-exchange mass spectrometry</title>
<p id="P66">All antibody:antigen complexes were equilibrated at 3:1 ratio in PBS (pH 7.1) at 4°C prior to labelling. The labelling reaction was initiated upon 10x dilution with 10 mM Tris (45% D2O) at 20 °C with an HDx3-PAL autosampler (Trajan Scientific and Medical, Ringwood, Australia) for a final composition of 40% D2O. The reaction was quenched after 3 min by a 5x dilution with 1% formic acid (FA, pH 2.2, 4°C), and 75 μL (20 pmol) was injected. Labelled sample was flowed through a p-Prepcell (Antec Scientific, Zoeterwoude, The Netherlands) at 50 μL/min in mobile phase A (0.23% FA) where electrochemical reduction was performed in pulse mode (El = 1.0 V, E2 = 0 V, tl = l s, t2 = 0.1 s) <sup>
<xref ref-type="bibr" rid="R92">92</xref>
</sup>, followed by online digestion with a pepsin (Enzymate BEH, Waters, Milford, MA) or nepenthesin-II column (Affipro, Prague, Czech Republic). Peptides were trapped (Waters ACQUITY UPLC BEH C18 Vanguard Pre-column, 130 Å, 1.7 μm, 2.1 mm × 5 mm), separated (ACQUITY UPLC BEH C18, 130 Å, 1.7 μm, l × 100mm) with an acetonitrile gradient and analyzed by ESI-MS (300-1600 m/z) with a Synapt G2-Si (Waters), with ion mobility enabled for the S dataset. Data-dependent MS/MS acquisition was applied to an unlabeled sample to generate a peptide map, and peptides were identified with a database search in Mascot. Replicate data was collected in triplicate in five separate batches with unique non-binding controls, and deuteration was assigned with HDExaminer v2 (Batch 1 to 4, Sierra Analytics, Modesto, CA) or MS Studio <sup>
<xref ref-type="bibr" rid="R93">93</xref>
</sup> (Batch 5). Full experimental parameters for each batch are outlined in <xref ref-type="supplementary-material" rid="SD2">Table S9</xref>. Finally, significant changes in deuteration was assigned based on two cutoffs (3 × SD and 1-p = 0.98) using MS Studio <sup>
<xref ref-type="bibr" rid="R94">94</xref>
</sup>.</p>
</sec>
</sec>
<sec id="S43">
<label>4.9</label>
<title>Surrogate virus neutralization assays</title>
<sec id="S44">
<label>a)</label>
<title>ACE2 competition assay by ELISA</title>
<p id="P67">Wells of NUNC® Immulon 4 HBX microtiter plates (Thermo Fisher) were coated overnight at 4°C with 50 ng/well of S in 100 μL PBS, pH 7.4. Next day, plates were blocked with 250 μL PBSC for 1 h at room temperature. For ACE2/V<sub>h</sub>H competitive binding to SARS-CoV2 S (Wuhan), 50 μL of human ACE2-Fc (ACROBiosystems, Cat#AC2-H5257) at 400 ng/mL was mixed with 50 μL of V<sub>h</sub>H at 1 μM, and then transferred to SARS-CoV-2 S coated microtiter plate wells. After 1 h incubation at room temperature, plates were washed 10 times with PBST and the ACE2-Fc binding was detected using 1 μg/mL goat anti-human IgG (Fc specific) HRP conjugate antibody (Sigma, Cat#A0170) in 100 μL PBSCT. After 10 washes with PBST, the peroxidase (HRP) activity was determined as described in <bold>
<italic>4.2a</italic>
</bold>.</p>
</sec>
<sec id="S45">
<label>b)</label>
<title>ACE2 competition assay by SPR</title>
<p id="P68">Standard SPR techniques were used for binding studies. All SPR assays were performed on a Biacore T200 instrument (Cytiva) at 25°C with HBS-EP running buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% Tween 20, pH 7.4) and CM5 sensor chips (Cytiva). Prior to SPR analyses all analytes in flow (V<sub>h</sub>Hs, ACE2) were SEC-purified on a Superdex 75™ Increase 10/300 GL column (Cytiva) in HBS-EP buffer at a flow rate of 0.8 mL/min to obtain monomeric proteins. V<sub>h</sub>Hs were analyzed for their ability to block the SARS-CoV-2 Wuhan S interaction with ACE2 using SPR dual injection experiments. V<sub>h</sub>Hs and ACE2 were flowed over the SARS-CoV-2 S surface at 40 μL/min in HBS-EP buffer. Dual injections consisted of injection of ACE2 (1 μM) for 150 s, followed by immediate injection of a mixture of ACE2 (1 μM) + V<sub>h</sub>H (at 20 – 40 × <italic>K</italic>
<sub>d</sub> concentration) for 150 s. The opposite orientation was also performed (V<sub>h</sub>H followed by V<sub>h</sub>H + ACE2). Surfaces were regenerated using a 12 s pulse of 10 mM glycine, pH 1.5, at a flow rate of 100 μL/min. All pairwise combinations of V<sub>h</sub>Hs and ACE2 were analyzed. V<sub>h</sub>Hs that competed with ACE2 for SARS-CoV-2 spike glycoprotein binding showed no increase in binding response during the second injection. Conversely, a binding response was seen during the second injection for V<sub>h</sub>Hs that did not compete with ACE2.</p>
</sec>
<sec id="S46">
<label>c)</label>
<title>ACE2 competition assay by flow cytometry</title>
<p id="P69">Experiments were performed as described in <bold>
<italic>4.3c</italic>
</bold>, except that biotinylated S/Vero E6 cells were mixed with V<sub>h</sub>Hs or V<sub>h</sub>H-Fcs instead of sera. Additionally, assays were performed against biotinylated SARS-CoV-2 Wuhan, Alpha, Beta, Gamma, Delta and Kappa as well as SARS-CoV S. As internal reference of competition experiments, competition assay with recombinant human ACE2-H6 in lieu of V<sub>h</sub>H was also included. A20.1, a <italic>C. difficile</italic> toxin A-specific V<sub>h</sub>H <sup>
<xref ref-type="bibr" rid="R82">82</xref>
</sup> was used as negative control V<sub>h</sub>H. Percent inhibition was calculated according the formula in <bold>4.3<italic>c</italic>
</bold>, with <italic>F</italic>
<sub>n</sub> and <italic>F</italic>
<sub>max</sub> relating to V<sub>h</sub>H not serum as the competitor.</p>
</sec>
</sec>
<sec id="S47">
<label>4.10</label>
<title>Pseudotyped and live virus neutralization assays</title>
<sec id="S48">
<label>a)</label>
<title>Pseudotyped virus neutralization assays</title>
<p id="P70">(i) Generation of SARS-CoV-2 spike pseudotyped lentiviral particles (LVP): HEK293T cells were plated in a 100-mm tissue culture dish and transfected the next day at about 75% confluency with a combination of a lentiviral transfer vector encoding eGFPLuc (addgene#119816), the packaging plasmid psPAX2 (addgene#12260), and a plasmid encoding the viral glycoprotein of interest SARS-CoV-2 Spike-ΔS1/S2-Δ20 expressed in pcDNA3.1<sup>+</sup>. Transfection was performed using the jetPRIME transfection reagent (Polyplus-transfection, Illkirch, France) according to the manufacturer’s protocol at a 1:1:1 (eGFPLuc:psPAX2:Spike) ratio for a total of 10 μg. The media was replaced at 24 h post transfection and complete media added to the plate. The supernatant from cell culture was harvested at 48, 72 and 96 h, each time replenished with fresh media. The combined supernatants were centrifuged at 800 <italic>g</italic> for 10 min and supernatants passed through a 0.45-μm syringe filter. Then, 1 volume of concentrator (40% [w/v] PEG-8000, 1.2 M NaCl, pH 7.0) was added to 3 volumes of supernatant, mixed for 1 min then incubated with constant rocking at 60 rpm for at least 4 h at 4°C. The mixture was centrifuged at 1600 <italic>g</italic> for 60 min at 4°C and the supernatant carefully discarded without disturbing the pellet. The pellet was then resuspended in PBS buffer at 1/10 of the original supernatant volume with gentle up-and-down pipetting, aliquoted and stored at −80°C. (ii) Viral neutralization assays: HEK293T-hACE2 cell line (BEI Resources, Manassas, VA, Cat#NR-52511) were seeded in poly-L-Lysine (PLL)-coated white, clear bottom 384-wells plate (NUNC, Thermo Fisher) at a density of 9,000 cells/well in 45 μL of media (DMEM without phenol red supplemented with 5% [v/v] FBS) and incubated for 24 h at 37°C, 5% CO<sub>2</sub>. The next day, a half-log serial dilution of each nanobody (V<sub>h</sub>H/V<sub>h</sub>H-Fc) to be tested was prepared at 4x the final concentration ranging from 0 to 50 μg/mL in complete media. Then, 20 μL of the 4x nanobody solution was added to each well and incubated for 10 min at 37°C, 5% CO<sub>2</sub>. After incubation, 20 μL of LVP master mix was added to each well and incubated a further 48 h at 37°C, 5% CO<sub>2</sub>. LVP master mix was prepared as follow: 10 μL of LVPs (as prepared above) were mixed with 20 μg/mL of polybrene (4x final concentration) and media for a final volume of 20 μL per well. Forty-eight hours later, 30 μL of the substrate buffer (324 mM Tris−HCl, 125 mM Tris-Base, 225 mM NaCl, 9 mM MgCL<sub>2</sub>, 15 mM dithiothreitol (DTT), 0.6 mM coenzyme A, 0.42 mg/mL D-luciferin, 3.3 mM ATP, 0.75% (v/v) Triton X-100, 6 mM sodium hydrosulfite) was added to each well. Then the plate was vortexed at 400 rpm for 2 min and luminescence read on a Synergy Neo2 plate reader (BioTek, Winooski, VT).</p>
</sec>
<sec id="S49">
<label>b)</label>
<title>Live virus neutralizations assays</title>
<p id="P71">Neutralization activity of antibodies to SARS-CoV-2 was determined with the microneutralization assay. In brief, V<sub>h</sub>H-Fc stocks were prepared at 1 mg/mL in PBS and sterilized by passing through 0.22-μm filters. Quantitative microneutralization assay was performed on Vero E6 cells with SARS-CoV-2 strains hCOV-19/Canada/ON-VIDO-01/2020, NR-53565;hCOV-19/England/204820464/2020, NR-54000; or hCOV-19/South Africa/KRISP-EC-K005321 /2020, NR-54008. In brief, 15 μg of antibody was diluted in 300 μL of infection media (1x DMEM, high glucose media supplemented with 1x nonessential amino acid, 100 U/mL penicillin-streptomycin, 1 mM sodium pyruvate, and 1% FBS), from which a subsequent 1:5 serial dilutions was carried out. Fifty microliters of each antibody dilution was mixed with 250 plaque-forming units (PFU) of virus in 50 μL volume. The virus/antibody mix was incubated at 37°C for 1 h. Fifty microliters of the virus/antibody mix was used to infect Vero E6 cells for 1 h at 37°C. The inoculum was removed and 100 μL of antibody dilution was added to each corresponding infected cell monolayer. Infection was incubated at 37°C for 72 h, from then they were fixed in 10% formaldehyde. Virus infection was detected with mouse mAb to SARS-CoV-2 nucleocapsid (N) (R&amp;D Systems, Minneapolis, MN, Cat#MAB10474) and counterstained with rabbit anti-mouse IgG-HRP (Rockland Immunochemicals, Inc., Limerick, PA) and developed with <italic>o</italic>-Phenylenediamine dihydrochloride (Sigma) and detected on BioTek Synergy H1 microplate reader at 490 nm. <italic>IC<sub>50</sub>
</italic> was determined from non-linear regression [Inhibitor] vs. response, Variable slope (four parameters) using GraphPad Prism version 9 (La Jolla, CA).</p>
</sec>
</sec>
<sec id="S50">
<label>4.11</label>
<title>
<italic>In vivo</italic> efficacy studies</title>
<sec id="S51">
<label>a)</label>
<title>In vivo challenge</title>
<p id="P72">Female Golden Syrian hamsters (81 – 90 g) were obtained from Charles River Laboratories (Saint-Constant, Canada) and maintained at the NRC small animal facility. All animal procedures and animal husbandry in this study were carried out in accordance to regulations and guidelines outlined under the Canadian Council on Animal Care and approved by the NRC Human Health Therapeutics Animal Care Committee. Sixty hamsters (six /treatment group) were prebled for 300 μL of blood followed by IP infusion with 1 mg of antibodies or with PBS 24 h before challenge. Baseline body weights were determined before challenge. The animals were then infected intranasally under ketamine/xylazine with 8.5 × 10<sup>4</sup> PFU (in 100 μL) of SARS-CoV-2. Daily weight and clinical symptoms were monitored for 5 days post-infection (dpi). At 5 dpi, animals were euthanized and their lungs were collected for virus titers determination and immunohistochemistry studies. Virus titer was determined by plaque assay on Vero cells.</p>
</sec>
<sec id="S52">
<label>b)</label>
<title>Immunohistochemistry</title>
<p id="P73">Lungs were immersed in 10% neutral buffered formalin and fixed for 1 week at room temperature and then transferred into 70% ethanol. All 4 lobes of right lung were processed and embedded in paraffin wax. The paraffin block was cut into 5-μm sections and placed on Superfrost Plus slides (Thermo Fisher). Sections were dried overnight and then subjected to immunohistochemistry (IHC) using a modified protocol F on the Bond-Max III fully automated staining system (Leica Biosystems, Wetzlar, Germany). All reagents from the Bond Polymer Refine Detection Kit DC9800 (Leica, Buffalo Grove, IL) were used for IHC. Immune cell infiltrate was detected using rabbit polyclonal antibodies against CD3 (1:500, Dako, Cat#A0452), and Iba-1 (ionized calcium binding adaptor protein, 1:5000, Dako, Cat#019-19741). Mouse anti-SARS-CoV-2 N monoclonal antibody (1:5000, R&amp;D Systems, Cat#MAB10474) was used for the detection of SARS-CoV-2. Following deparaffinization and rehydration, sections were pre-treated with the Epitope Retrieval Solution 1 (ER1, Citrate buffer, pH 5.0) or Epitope Retrieval Solution 2 (ER2, EDTA buffer, pH 8.8) at 98°C for 20 min. Epitopes were exposed using ER1 for Iba-1 and SARS-CoV-2 N and ER2 for CD3. After washing steps, non-specific endogenous peroxidases were quenched using peroxidase block for 5 min. Sections were washed again and then incubated for 15 min at room temperature with primary antibodies. After washes, sections were incubated with polymer refine for 8 min at room temperature and developed with 3, 3’-diaminobenzidine (DAB) chromogen for 10 min. Sections were washed and counterstained for 5 min with hematoxylin, dehydrated, cleared and mounted. Each antibody was titrated and optimized for the detection of positive signals. Negative controls included omission of primary antibody and incubation with secondary antibody alone as well as lung tissue from naïve animals.</p>
<p id="P74">The DeadEnd Colorimetric TUNEL (<underline>T</underline>dT-mediated d<underline>U</underline>TP <underline>N</underline>ick-<underline>E</underline>nd Labeling) System (Promega Madison, WI, Cat#G7132) was used to detect apoptosis as per manufacturer’s instructions. Briefly, sections were deparaffinized and permeabilized with proteinase K for 15 min followed by labeling with biotinylated nucleotides in the presence of recombinant terminal deoxynucleotidyl tranferase. Sections were then incubated with horseradish peroxidase-streptavidin conjugate and developed using DAB for 10 min. Sections were washed and counterstained for 5 min with hematoxylin, dehydrated, cleared and mounted.</p>
<p id="P75">All images were acquired with an Olympus IX81 microscope, equipped with a DP27 color CCD camera using the 20x objective (Shinjuku, Tokyo, Japan).</p>
</sec>
</sec>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplemental Figures</label>
<media xlink:href="EMS141181-supplement-Supplemental_Figures.pdf" mimetype="application" mime-subtype="pdf" id="N69025" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD2">
<label>Supplemental Tables</label>
<media xlink:href="EMS141181-supplement-Supplemental_Tables.pdf" mimetype="application" mime-subtype="pdf" id="N69034" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S53">
<title>Acknowledgements</title>
<p>We thank Bassam Hallis for contributing SARS-Related Coronavirus 2, Isolate hCoV-19/England/204820464/2020, NR-54000, and Alex Sigal and Tulio de Oliveira for contributing SARS-Related Coronavirus 2, Isolate hCoV-19/South Africa/KRISP-EC-K005321/2020, NR-54008; both virus isolates were obtained through BEI Resources, NIAID, NIH. We thank the NRC Animal Resources team for animal husbandry and technical support, and Luc Lemay and Jennifer Wellman for technical support in the CL3. We thank Sonia Leclerc and Julie Haukenfrers for performing DNA sequencing. We thank Qingling Yang and Shannon Ryan for assistance with expression of ACE2-H6 and His tagged and Fc-fused RBD/SD1, and Mary Foss for assistance with aerosolization studies. We thank the NRC Mammalian Cell Expression Section for assistance with production of recombinant proteins and Joline Cormier for contribution to protein samples management. We thank Alina Burlacu for generating the CHO-SPK cells and Tahir Maqbool for his support with llama immunizations. We thank Unchained Labs (Pleasanton, CA) for conducting isothermal chemical denaturation experiments. This work was supported by funding from the Pandemic Response Challenge Program of the National Research Council Canada and in part by a CIHR grant (OV1 - 170355) to M.A.L.</p>
</ack>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krause</surname>
<given-names>PR</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Variants and Vaccines</article-title>
<source>N Engl J Med</source>
<year>2021</year>
<volume>385</volume>
<fpage>179</fpage>
<lpage>186</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaqroun</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hartard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schvoerer</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants</article-title>
<source>Viruses</source>
<year>2021</year>
<volume>13</volume>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Planas</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization</article-title>
<source>Nature</source>
<year>2021</year>
<volume>596</volume>
<fpage>276</fpage>
<lpage>280</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>2348</fpage>
<lpage>2361</lpage>
<elocation-id>e2346</elocation-id>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madhi</surname>
<given-names>SA</given-names>
</name>
<etal/>
</person-group>
<article-title>Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant</article-title>
<source>N Engl J Med</source>
<year>2021</year>
<volume>384</volume>
<fpage>1885</fpage>
<lpage>1898</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<etal/>
</person-group>
<article-title>Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies</article-title>
<source>Nat Med</source>
<year>2021</year>
<volume>27</volume>
<fpage>717</fpage>
<lpage>726</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7</article-title>
<source>Nature</source>
<year>2021</year>
<volume>593</volume>
<fpage>130</fpage>
<lpage>135</lpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaku</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19</article-title>
<source>Cell Rep</source>
<year>2021</year>
<volume>36</volume>
<elocation-id>109385</elocation-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ke</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>
<article-title>Structures and distributions of SARS-CoV-2 spike proteins on intact virions</article-title>
<source>Nature</source>
<year>2020</year>
<volume>588</volume>
<fpage>498</fpage>
<lpage>502</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title>
<source>Nature</source>
<year>2020</year>
<volume>581</volume>
<fpage>215</fpage>
<lpage>220</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</article-title>
<source>Science</source>
<year>2020</year>
<volume>367</volume>
<fpage>1444</fpage>
<lpage>1448</lpage>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wrapp</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title>
<source>Science</source>
<year>2020</year>
<volume>367</volume>
<fpage>1260</fpage>
<lpage>1263</lpage>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<fpage>281</fpage>
<lpage>292</lpage>
<elocation-id>e286</elocation-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cerutti</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>
<article-title>Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite</article-title>
<source>Cell Host Microbe</source>
<year>2021</year>
<volume>29</volume>
<fpage>819</fpage>
<lpage>833</lpage>
<elocation-id>e817</elocation-id>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cerutti</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>
<article-title>Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain</article-title>
<source>Cell Rep</source>
<year>2021</year>
<volume>37</volume>
<elocation-id>109928</elocation-id>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCallum</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>2332</fpage>
<lpage>2347</lpage>
<elocation-id>e2316</elocation-id>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suryadevara</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>
<article-title>Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>2316</fpage>
<lpage>2331</lpage>
<elocation-id>e2315</elocation-id>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<elocation-id>4196</elocation-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chi</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group>
<article-title>A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>650</fpage>
<lpage>655</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>
<article-title>Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2</article-title>
<source>Euro Surveill</source>
<year>2020</year>
<volume>25</volume>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<elocation-id>3618</elocation-id>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Esparza</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Brody</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme</article-title>
<source>Sci Rep</source>
<year>2020</year>
<volume>10</volume>
<elocation-id>22370</elocation-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiang</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2</article-title>
<source>Science</source>
<year>2020</year>
<volume>370</volume>
<fpage>1479</fpage>
<lpage>1484</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schoof</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike</article-title>
<source>Science</source>
<year>2020</year>
<volume>370</volume>
<fpage>1473</fpage>
<lpage>1479</lpage>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Custodio</surname>
<given-names>TF</given-names>
</name>
<etal/>
</person-group>
<article-title>Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<elocation-id>5588</elocation-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanke</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<elocation-id>4420</elocation-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2</article-title>
<source>Sci Rep</source>
<year>2020</year>
<volume>10</volume>
<elocation-id>17806</elocation-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huo</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2</article-title>
<source>Nat Struct Mol Biol</source>
<year>2020</year>
<volume>27</volume>
<fpage>846</fpage>
<lpage>854</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wrapp</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<fpage>1004</fpage>
<lpage>1015</lpage>
<elocation-id>e1015</elocation-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chi</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group>
<article-title>Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<elocation-id>4528</elocation-id>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koenig</surname>
<given-names>PA</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape</article-title>
<source>Science</source>
<year>2021</year>
<volume>371</volume>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models</article-title>
<source>Cell</source>
<year>2020</year>
<volume>183</volume>
<fpage>429</fpage>
<lpage>441</lpage>
<elocation-id>e416</elocation-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pymm</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2021</year>
<volume>118</volume>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants</article-title>
<source>Nature</source>
<year>2021</year>
<volume>595</volume>
<fpage>278</fpage>
<lpage>282</lpage>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>Q</given-names>
</name>
<etal/>
</person-group>
<article-title>Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein</article-title>
<source>J Nanobiotechnology</source>
<year>2021</year>
<volume>19</volume>
<fpage>33</fpage>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rujas</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>
<article-title>Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<elocation-id>3661</elocation-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>A high-affinity RBD-targeting nanobody improves fusion partner’s potency against SARS-CoV-2</article-title>
<source>PLoS Pathog</source>
<year>2021</year>
<volume>17</volume>
<elocation-id>e1009328</elocation-id>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<elocation-id>4635</elocation-id>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schepens</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models</article-title>
<source>Sci Transl Med</source>
<year>2021</year>
<elocation-id>eabi7826</elocation-id>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group>
<article-title>A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration</article-title>
<source>Cell Rep</source>
<year>2021</year>
<volume>37</volume>
<elocation-id>109869</elocation-id>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nambulli</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses</article-title>
<source>bioRxiv</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bracken</surname>
<given-names>CJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2</article-title>
<source>Nat Chem Biol</source>
<year>2021</year>
<volume>17</volume>
<fpage>113</fpage>
<lpage>121</lpage>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zupancic</surname>
<given-names>JM</given-names>
</name>
<etal/>
</person-group>
<article-title>Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS-CoV-2 Variants</article-title>
<source>Adv Ther (Weinh)</source>
<year>2021</year>
<volume>4</volume>
<elocation-id>2100099</elocation-id>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Gentili</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hacohen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Regev</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<elocation-id>5506</elocation-id>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<elocation-id>4676</elocation-id>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>
<article-title>The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates</article-title>
<source>Elife</source>
<year>2021</year>
<volume>10</volume>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huo</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<elocation-id>5469</elocation-id>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamers-Casterman</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Naturally occurring antibodies devoid of light chains</article-title>
<source>Nature</source>
<year>1993</year>
<volume>363</volume>
<fpage>446</fpage>
<lpage>448</lpage>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="web">
<comment>
<ext-link ext-link-type="uri" xlink:href="https://ClinicalTrials.gov/show/NCT04884295">https://ClinicalTrials.gov/show/NCT04884295</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Detalle</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection</article-title>
<source>Antimicrob Agents Chemother</source>
<year>2016</year>
<volume>60</volume>
<fpage>6</fpage>
<lpage>13</lpage>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Delgado</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Inhaled nanobodies against COVID-19</article-title>
<source>Nat Rev Immunol</source>
<year>2020</year>
<volume>20</volume>
<fpage>593</fpage>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gai</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential</article-title>
<source>MedComm (Beijing)</source>
<year>2021</year>
<volume>2</volume>
<fpage>101</fpage>
<lpage>113</lpage>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2009</year>
<volume>106</volume>
<fpage>19970</fpage>
<lpage>19974</lpage>
</element-citation>
</ref>
<ref id="R54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Hoek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pyrc</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Berkhout</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Human coronavirus NL63, a new respiratory virus</article-title>
<source>FEMS Microbiol Rev</source>
<year>2006</year>
<volume>30</volume>
<fpage>760</fpage>
<lpage>773</lpage>
</element-citation>
</ref>
<ref id="R55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Myers</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Pace</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Scholtz</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Denaturant m values and heat capacity changes: relation to changes in accessible surface areas of protein unfolding</article-title>
<source>Protein Sci</source>
<year>1995</year>
<volume>4</volume>
<fpage>2138</fpage>
<lpage>2148</lpage>
</element-citation>
</ref>
<ref id="R56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vincke</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold</article-title>
<source>J Biol Chem</source>
<year>2009</year>
<volume>284</volume>
<fpage>3273</fpage>
<lpage>3284</lpage>
</element-citation>
</ref>
<ref id="R57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ewert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cambillau</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Conrath</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pluckthun</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains</article-title>
<source>Biochemistry</source>
<year>2002</year>
<volume>41</volume>
<fpage>3628</fpage>
<lpage>3636</lpage>
</element-citation>
</ref>
<ref id="R58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Govaert</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Dual beneficial effect of interloop disulfide bond for single domain antibody fragments</article-title>
<source>J Biol Chem</source>
<year>2012</year>
<volume>287</volume>
<fpage>1970</fpage>
<lpage>1979</lpage>
</element-citation>
</ref>
<ref id="R59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dumoulin</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Single-domain antibody fragments with high conformational stability</article-title>
<source>Protein Sci</source>
<year>2002</year>
<volume>11</volume>
<fpage>500</fpage>
<lpage>515</lpage>
</element-citation>
</ref>
<ref id="R60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>James</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Balmer</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Protein Footprinting, Conformational Dynamics, and Core Interface-Adjacent Neutralization “Hotspots” in the SARS-CoV-2 Spike Protein Receptor Binding Domain/Human ACE2 Interaction</article-title>
<source>J Am Soc Mass Spectrom</source>
<year>2021</year>
<volume>32</volume>
<fpage>1593</fpage>
<lpage>1600</lpage>
</element-citation>
</ref>
<ref id="R61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>1010</fpage>
<lpage>1014</lpage>
</element-citation>
</ref>
<ref id="R62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dumet</surname>
<given-names>CJY</given-names>
</name>
<name>
<surname>Musnier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Riviere</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Poirier</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Watier</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bourquard</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Poupon</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Exploring epitope and functional diversity of anti-SARS-CoV2 antibodies using AI-based methods</article-title>
<source>BioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henderson</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>Controlling the SARS-CoV-2 spike glycoprotein conformation</article-title>
<source>Nat Struct Mol Biol</source>
<year>2020</year>
<volume>27</volume>
<fpage>925</fpage>
<lpage>933</lpage>
</element-citation>
</ref>
<ref id="R64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henderson</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>Controlling the SARS-CoV-2 Spike Glycoprotein Conformation</article-title>
<source>bioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure-based development of human antibody cocktails against SARS-CoV-2</article-title>
<source>Cell Res</source>
<year>2021</year>
<volume>31</volume>
<fpage>101</fpage>
<lpage>103</lpage>
</element-citation>
</ref>
<ref id="R66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voss</surname>
<given-names>WN</given-names>
</name>
<etal/>
</person-group>
<article-title>Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes</article-title>
<source>Science</source>
<year>2021</year>
<volume>372</volume>
<fpage>1108</fpage>
<lpage>1112</lpage>
</element-citation>
</ref>
<ref id="R67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates</article-title>
<source>bioRxiv</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization</article-title>
<source>Cell Host Microbe</source>
<year>2021</year>
<volume>29</volume>
<fpage>747</fpage>
<lpage>751</lpage>
<elocation-id>e744</elocation-id>
</element-citation>
</ref>
<ref id="R69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients</article-title>
<source>Cell Rep</source>
<year>2021</year>
<volume>34</volume>
<elocation-id>108915</elocation-id>
</element-citation>
</ref>
<ref id="R70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tostanoski</surname>
<given-names>LH</given-names>
</name>
<etal/>
</person-group>
<article-title>Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters</article-title>
<source>Nat Med</source>
<year>2020</year>
<volume>26</volume>
<fpage>1694</fpage>
<lpage>1700</lpage>
</element-citation>
</ref>
<ref id="R71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies</article-title>
<source>Nature</source>
<year>2020</year>
<volume>588</volume>
<fpage>682</fpage>
<lpage>687</lpage>
</element-citation>
</ref>
<ref id="R72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<etal/>
</person-group>
<article-title>Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>828</fpage>
<lpage>842</lpage>
<elocation-id>e816</elocation-id>
</element-citation>
</ref>
<ref id="R73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Structural basis of a shared antibody response to SARS-CoV-2</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>1119</fpage>
<lpage>1123</lpage>
</element-citation>
</ref>
<ref id="R74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>YNA</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>C-L</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Olaluwoye</surname>
<given-names>OS</given-names>
</name>
<name>
<surname>Wilen</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Kaoud</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Azouz</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Qerqez</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Bohanon</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>DiVenere</surname>
<given-names>AM</given-names>
</name>
<etal/>
</person-group>
<article-title>Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses</article-title>
<source>bioRxiv</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schepens</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Nanobodies(R) specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion</article-title>
<source>J Infect Dis</source>
<year>2011</year>
<volume>204</volume>
<fpage>1692</fpage>
<lpage>1701</lpage>
</element-citation>
</ref>
<ref id="R76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stuible</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cells</article-title>
<source>J Biotechnol</source>
<year>2021</year>
<volume>326</volume>
<fpage>21</fpage>
<lpage>27</lpage>
</element-citation>
</ref>
<ref id="R77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akache</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant</article-title>
<source>Sci Rep</source>
<year>2021</year>
<volume>11</volume>
<elocation-id>21849</elocation-id>
</element-citation>
</ref>
<ref id="R78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colwill</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>
<article-title>A “Made-in-Canada” serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination</article-title>
<source>medRxiv</source>
<year>2021</year>
<elocation-id>2021.2010.2025.21265476</elocation-id>
</element-citation>
</ref>
<ref id="R79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galipeau</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2</article-title>
<source>EBioMedicine</source>
<year>2021</year>
<volume>74</volume>
<elocation-id>103700</elocation-id>
</element-citation>
</ref>
<ref id="R80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wrapp</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation</article-title>
<source>bioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossotti</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Streamlined method for parallel identification of single domain antibodies to membrane receptors on whole cells</article-title>
<source>Biochim Biophys Acta</source>
<year>2015</year>
<volume>1850</volume>
<fpage>1397</fpage>
<lpage>1404</lpage>
</element-citation>
</ref>
<ref id="R82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hussack</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>
<article-title>Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain</article-title>
<source>J Biol Chem</source>
<year>2011</year>
<volume>286</volume>
<fpage>8961</fpage>
<lpage>8976</lpage>
</element-citation>
</ref>
<ref id="R83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henry</surname>
<given-names>KA</given-names>
</name>
<etal/>
</person-group>
<article-title>Isolation of TGF-beta-neutralizing single-domain antibodies of predetermined epitope specificity using next-generation DNA sequencing</article-title>
<source>Protein Eng Des Sel</source>
<year>2016</year>
<volume>29</volume>
<fpage>439</fpage>
<lpage>443</lpage>
</element-citation>
</ref>
<ref id="R84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossotti</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>
<article-title>Camelid single-domain antibodies raised by DNA immunization are potent inhibitors of EGFR signaling</article-title>
<source>Biochem J</source>
<year>2019</year>
<volume>476</volume>
<fpage>39</fpage>
<lpage>50</lpage>
</element-citation>
</ref>
<ref id="R85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossotti</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>
<article-title>Method for Sorting and Pairwise Selection of Nanobodies for the Development of Highly Sensitive Sandwich Immunoassays</article-title>
<source>Anal Chem</source>
<year>2015</year>
<volume>87</volume>
<fpage>11907</fpage>
<lpage>11914</lpage>
</element-citation>
</ref>
<ref id="R86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poulain</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Rapid protein production from stable CHO cell pools using plasmid vector and the cumate gene-switch</article-title>
<source>J Biotechnol</source>
<year>2017</year>
<volume>255</volume>
<fpage>16</fpage>
<lpage>27</lpage>
</element-citation>
</ref>
<ref id="R87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henry</surname>
<given-names>KA</given-names>
</name>
<etal/>
</person-group>
<article-title>Stability-Diversity Tradeoffs Impose Fundamental Constraints on Selection of Synthetic Human VH/VL Single-Domain Antibodies from In Vitro Display Libraries</article-title>
<source>Front Immunol</source>
<year>2017</year>
<volume>8</volume>
<fpage>1759</fpage>
</element-citation>
</ref>
<ref id="R88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wafer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kloczewiak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Polleck</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Isothermal chemical denaturation of large proteins: Path-dependence and irreversibility</article-title>
<source>Anal Biochem</source>
<year>2017</year>
<volume>539</volume>
<fpage>60</fpage>
<lpage>69</lpage>
</element-citation>
</ref>
<ref id="R89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saerens</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Conrath</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Govaert</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Muyldermans</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains</article-title>
<source>J Mol Biol</source>
<year>2008</year>
<volume>377</volume>
<fpage>478</fpage>
<lpage>488</lpage>
</element-citation>
</ref>
<ref id="R90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delfin-Riela</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rossotti</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Echaides</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gonzalez-Sapienza</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>A nanobody-based test for highly sensitive detection of hemoglobin in fecal samples</article-title>
<source>Anal Bioanal Chem</source>
<year>2020</year>
<volume>412</volume>
<fpage>389</fpage>
<lpage>396</lpage>
</element-citation>
</ref>
<ref id="R91">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delfin-Riela</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rossotti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Alvez-Rosado</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Leizagoyen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gonzalez-Sapienza</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Highly Sensitive Detection of Zika Virus Nonstructural Protein 1 in Serum Samples by a Two-Site Nanobody ELISA</article-title>
<source>Biomolecules</source>
<year>2020</year>
<volume>10</volume>
</element-citation>
</ref>
<ref id="R92">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Comamala</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>
<article-title>Hydrogen/deuterium exchange mass spectrometry with improved electrochemical reduction enables comprehensive epitope mapping of a therapeutic antibody to the cysteine-knot containing vascular endothelial growth factor</article-title>
<source>Anal Chim Acta</source>
<year>2020</year>
<volume>1115</volume>
<fpage>41</fpage>
<lpage>51</lpage>
</element-citation>
</ref>
<ref id="R93">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rey</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Mass spec studio for integrative structural biology</article-title>
<source>Structure</source>
<year>2014</year>
<volume>22</volume>
<fpage>1538</fpage>
<lpage>1548</lpage>
</element-citation>
</ref>
<ref id="R94">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raval</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Improving Spectral Validation Rates in Hydrogen-Deuterium Exchange Data Analysis</article-title>
<source>Anal Chem</source>
<year>2021</year>
<volume>93</volume>
<fpage>4246</fpage>
<lpage>4254</lpage>
</element-citation>
</ref>
<ref id="R95">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Stecher</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>MEGA11: Molecular Evolutionary Genetics Analysis Version 11</article-title>
<source>Mol Biol Evol</source>
<year>2021</year>
<volume>38</volume>
<fpage>3022</fpage>
<lpage>3027</lpage>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Fig. 1</label>
<caption>
<title>Selection, binding affinity and subunit/domain specificity of anti-SARS-CoV-2 S V<sub>H</sub>Hs.</title>
<p>V<sub>h</sub>Hs are grouped based on their specificity for NTD, RBD or S2 and color-coded based on their epitope bin designation (<italic>see</italic> <xref ref-type="fig" rid="F5">Fig. 5A</xref>). <bold>A</bold>) Library origin, relative proportion and subunit/domain specificity of the 37 anti-SARS-CoV-2 S V<sub>h</sub>Hs selected from the Green and Red libraries by employing six panning strategies P1 – P6. Binding specificity patterns in P1 – P6 reflect the selection strategies employed. For the Red library, P1 also selected for a V<sub>h</sub>H (ARes09, grey, unlabeled) that was specific to the resistin trimerization domain of the S used for immunization and panning. Green library V<sub>h</sub>Hs were isolated from the llama immunized once with S and three times with RBD. Red library V<sub>h</sub>Hs were isolated from the llama immunized four times with S. <bold>B</bold>) Diversity of the 37 SARS-CoV-2 S V<sub>h</sub>Hs shown in terms of CDR3 length. The number of V<sub>h</sub>Hs derived from each of the two libraries are shown. <bold>C</bold>) On-/off-rate maps summarizing V<sub>h</sub>H kinetic rate constants, <italic>k<sub>a</sub>s</italic> and k<sub>d</sub>s, determined by SPR. Diagonal lines represent equilibrium dissociation constants, <italic>K</italic>
<sub>d</sub>s (<italic>see</italic> also <xref ref-type="table" rid="T1">Table 1</xref>). Maps were constructed using the V<sub>h</sub>H binding data (<xref ref-type="supplementary-material" rid="SD1">Fig. S3</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S2</xref>) against SARS-CoV-2 Wuhan S (all except 12 and MRed05) or RBD/SD1 (12 and MRed05). V<sub>h</sub>H subunit/domain specificities were determined by SPR and ELISA (<xref ref-type="supplementary-material" rid="SD1">Fig. S3</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S2</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S3</xref>). Anti-SARS-CoV S VHH-72 which cross-reacts with SARS-CoV-2 RBD <sup>
<xref ref-type="bibr" rid="R29">29</xref>
</sup> and the monomeric ACE2 (ACE2-H6) are included as benchmark/reference binders. <bold>D</bold>) Binding of SARS-CoV-2 S V<sub>h</sub>H-Fcs to S-expressing CHO cells (CHO-SPK) obtained by flow cytometry. Apparent <italic>EC</italic>
<sub>50</sub>s (<italic>FC</italic>
<sub>50</sub>apps) were obtained from graphs in <xref ref-type="supplementary-material" rid="SD1">Fig. S4</xref> and are included in <xref ref-type="table" rid="T1">Table 1</xref>. Black open circle, VHH-72 benchmark.</p>
</caption>
<graphic xlink:href="EMS141181-f001"/>
<graphic xlink:href="EMS141181-f002"/>
</fig>
<fig id="F2" position="float">
<label>Fig. 2</label>
<caption>
<title>Cross-reactivity of anti-SARS-CoV-2 S V<sub>h</sub>Hs.</title>
<p>Data are organized based on V<sub>h</sub>H subunit/domain specificity and epitope bin designation (<italic>see</italic> <xref ref-type="fig" rid="F5">Fig. 5A</xref>). <bold>A</bold>) ELISA showing the cross-reactivity of V<sub>h</sub>Hs against various coronavirus spike glycoprotein fragments, S, S1, S2, RBD and NTD. Shades of red represent binding, colorless boxes represent no binding. Assays were performed at a single V<sub>h</sub>H-Fc concentration. The “isotype” control (A20.1 V<sub>h</sub>H-Fc) shows no binding to S. Anti-SARS-CoV VHH-72 and ACE2-Fc were included as references. The phylogenetic tree of spike glycoproteins was constructed using MEGA11 <sup>
<xref ref-type="bibr" rid="R95">95</xref>
</sup>. <bold>B, C</bold>) On-/off-rate maps summarizing V<sub>h</sub>H kinetic rate constants, <italic>k</italic>
<sub>a</sub>s and <italic>k</italic>
<sub>d</sub>s determined by SPR for the binding of V<sub>h</sub>Hs to SARS-CoV S (<bold>B</bold>) and SARS-CoV-2 Alpha and Beta S (<bold>C</bold>). Diagonal lines represent equilibrium dissociation constants, <italic>K</italic>
<sub>d</sub>s (<italic>see</italic> also <xref ref-type="table" rid="T1">Table 1</xref>). Maps were constructed using the V<sub>h</sub>H binding data from <xref ref-type="supplementary-material" rid="SD1">Fig. S5</xref> and <xref ref-type="supplementary-material" rid="SD2">Table S4</xref>. Anti-SARS-CoV VHH-72 and the monomeric ACE2 (ACE2-H6) are included as benchmark/reference binders.</p>
</caption>
<graphic xlink:href="EMS141181-f003"/>
</fig>
<fig id="F3" position="float">
<label>Fig. 3</label>
<caption>
<title>Stability of anti-SARS-CoV-2 S V<sub>h</sub>Hs.</title>
<p>
<bold>A)</bold> Representative SEC profile demonstrating the aggregation resistance of V<sub>h</sub>Hs. See <xref ref-type="supplementary-material" rid="SD1">Fig. S6</xref> for the full dataset. <bold>B</bold>) Summary of V<sub>h</sub>H <italic>T</italic>
<sub>m</sub> data. <italic>T</italic>
<sub>m</sub>S were obtained from plots of % folded <italic>vs</italic> temperature (<xref ref-type="supplementary-material" rid="SD1">Fig. S7</xref>; <xref ref-type="supplementary-material" rid="SD2">Table S5</xref>). <bold>C</bold>) Summary of V<sub>h</sub>H Δ<italic>G</italic>
<sup>0</sup> data. Δ<italic>G</italic>
<sup>0</sup> (as well as other thermodynamic parameters, <italic>C</italic>
<sub>m</sub> and <italic>m</italic> values) are reported in <xref ref-type="supplementary-material" rid="SD2">Table S5</xref>. <bold>D</bold>) <italic>In vivo</italic> stability and persistence of V<sub>h</sub>Hs. Stability and persistence were determined by monitoring the concentration of a representative V<sub>h</sub>H-Fc (1d) in hamster blood at various days post-injection by ELISA. VHH72-Fc was used as the benchmark. <bold>E</bold>) Stability of V<sub>h</sub>Hs against aerosolization. Summary of % recovery of all (<bold>i</bold>) and lead (<bold>ii</bold>) V<sub>h</sub>Hs are shown. Percent recovery represents the proportion of a V<sub>h</sub>H that remained soluble monomer following aerosolization. Graphs were generated based on the data in <xref ref-type="supplementary-material" rid="SD1">Fig. S9A</xref> and <xref ref-type="supplementary-material" rid="SD2">Table S6</xref>. Open circle in (<bold>i</bold>) represents benchmark VHH-72. (<bold>iii</bold>) Activity of pre- <italic>vs</italic> post-aerosolized V<sub>h</sub>Hs expressed in terms of antigen binding (<italic>EC</italic>
<sub>50</sub>). <italic>EC</italic>
<sub>50</sub>s were determined by ELISA. V<sub>h</sub>Hs in “<bold>B</bold>”, “<bold>C</bold>”, “<bold>E(i)</bold>” and “<bold>E(ii)</bold>” are color-coded based on their epitope bin designation (<italic>see</italic> <xref ref-type="fig" rid="F5">Fig. 5A</xref>).</p>
</caption>
<graphic xlink:href="EMS141181-f004"/>
</fig>
<fig id="F4" position="float">
<label>Fig. 4</label>
<caption>
<title>
<italic>In vitro</italic> neutralization potency of anti-SARS-CoV-2 S V<sub>h</sub>H-Fcs.</title>
<p>
<bold>A</bold>) Summary of <italic>IC</italic>
<sub>50</sub>s obtained by surrogate (SVNA), pseudotyped (PVNA) and live (LVNA) virus neutralization assays against SARS-CoV-2 Wuhan. <bold>B</bold>) Summary of <italic>IC</italic>
<sub>50</sub>s obtained by SVNAs against SARS-CoV-2 variants Wuhan, Alpha, Beta, Gamma, Delta and Kappa and SARS-CoV. <bold>C</bold>) Summary of <italic>IC</italic>
<sub>50</sub>s obtained by LVNAs for V<sub>h</sub>H-Fcs against Wuhan, Alpha and Beta SARS-CoV-2 variants. See also <xref ref-type="table" rid="T2">Table 2</xref> for <italic>IC</italic>
<sub>50</sub> values. Graphs were generated based on the data in <xref ref-type="supplementary-material" rid="SD1">Fig. S12</xref> – <xref ref-type="supplementary-material" rid="SD1">Fig. S15</xref> and <xref ref-type="supplementary-material" rid="SD2">Table S8</xref>. Data are organized based on subunit/domain specificity and epitope bin. Data are mean ± s.e.m. of technical duplicates. Black open circle, VHH-72 benchmark. V<sub>h</sub>Hs are color-coded based on their epitope bin designation (<italic>see</italic> <xref ref-type="fig" rid="F5">Fig. 5A</xref>).</p>
</caption>
<graphic xlink:href="EMS141181-f005"/>
</fig>
<fig id="F5" position="float">
<label>Fig. 5</label>
<caption>
<title>Epitope binning and mapping.</title>
<p>
<bold>A</bold>) Summary of epitope bins identified by SPR and ELISA (<italic>see</italic> <xref ref-type="supplementary-material" rid="SD1">Fig. S16</xref>). Bins are color-coded. <bold>B – D</bold>) HDX/MS epitope mapping of V<sub>h</sub>Hs binding RBD (<bold>B</bold>), NTD (<bold>C</bold>) and S2 (<bold>D</bold>). Changes in deuteration are mapped as colored rectangles corresponding to primary sequences. Stabilizations are shown in green, and destabilizations are shown in red, while regions with no significant changes in deuteration are shown in grey and missing coverage in white. Key structural features are highlighted by lines below the amino acid sequence, including the ACE2 binding site (blue), five mutations from VoCs, and N-linked glycans are included for reference. S2 subunit is shown partially.</p>
</caption>
<graphic xlink:href="EMS141181-f006"/>
</fig>
<fig id="F6" position="float">
<label>Fig. 6</label>
<caption>
<title>V<sub>h</sub>H-Fcs showed strong protective efficacy in hamsters challenged with SARS-CoV-2.</title>
<p>
<bold>A</bold>) Lung viral load in V<sub>h</sub>H-Fc-treated (VHH-72 benchmark, 1d, 05, MRed05, SR01, S2A3, 1d/MRed05, 1d/SR01) and control groups treated with PBS or isotype A20.1 V<sub>h</sub>H-Fc at 5 dpi. PFU, plaque-forming unit. <bold>B</bold>) Percent body weight change for antibody-treated and control groups. <bold>C</bold>) Percent body weight change at 5 dpi. In “<bold>A</bold>” and “<bold>C</bold>”, treatment effects, assessed by one-way ANOVA with Dunnett’s multiple comparison post hoc test, were significant (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 or ****p&lt;0.0001). Dunnett’s test was performed by comparing treatment groups against the isotype control. ns, not significant. <bold>D</bold>) Correlation curve of body weight change <italic>vs</italic> viral titer at 5 dpi. A strong negative correlation (r = −0.9436, p&lt;0.0001) between body weight change and lung viral titer was observed. <bold>E</bold>) Immunohistochemical demonstration of SARS-CoV-2 nucleocapsid (N) protein in the lungs of V<sub>h</sub>H-Fcs-treated animals. Untreated (PBS) and A20.1 isotype-treated animals showed strong viral N protein immunoreactivity which was mainly found in large multifocal patches of consolidated areas. Black arrow indicates the presence of viral N protein in bronchiolar epithelial cells. Omission of anti-nucleocapsid antibody eliminated the staining (Negative). Shown also is the absence of staining in healthy animals (Naive). A marked reduction in viral N protein staining was seen in all lung tissues examined from V<sub>h</sub>H-Fc-treated animals (middle and bottom panels). While no staining was observed in 05, MRed05, 1d/SR01 and 1d/MRed05, small foci of viral N protein was detected in VHH-72, 1d, SR01 and S2A3. Representative images are shown from a single experiment.</p>
</caption>
<graphic xlink:href="EMS141181-f007"/>
</fig>
<table-wrap id="T1" position="float" orientation="portrait">
<label>Table 1</label>
<caption>
<title>Binding characteristics of SARS-CoV-2 VHHs</title>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" valign="middle" rowspan="2">V<sub>h</sub>H/ACE2</th>
<th align="center" valign="middle" colspan="2">Epitope</th>
<th align="center" valign="middle">SARS-CoV-2 Wuhan S</th>
<th align="center" valign="middle" colspan="2">SARS-CoV-2 Alpha S</th>
<th align="center" valign="middle" colspan="2">SARS-CoV-2 Beta S</th>
<th align="center" valign="middle" colspan="2">SARS-CoV S</th>
<th align="center" valign="middle">SARS-CoV-2 S expressing cells<sup>
<xref ref-type="table-fn" rid="TFN7">g</xref>
</sup>
</th>
</tr>
<tr>
<th align="center" valign="middle">bin</th>
<th align="center" valign="middle">type</th>
<th align="center" valign="middle">SPR (<italic>K</italic>
<sub>D</sub>, nM)</th>
<th align="center" valign="middle">ELISA<sup>6</sup>
</th>
<th align="center" valign="middle">SPR (<italic>K</italic>
<sub>D</sub>, nM)</th>
<th align="center" valign="middle">ELISA<sup>
<xref ref-type="table-fn" rid="TFN5">e</xref>
</sup>
</th>
<th align="center" valign="middle">SPR (<italic>K</italic>
<sub>D</sub>, nM)</th>
<th align="center" valign="middle">ELISA<sup>6</sup>
</th>
<th align="center" valign="middle">SPR (<italic>K</italic>
<sub>D</sub>, nM)</th>
<th align="center" valign="middle">FC (<italic>EC</italic>
<sub>50</sub>app nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle" colspan="11">
<bold>RBD-specific V<sub>h</sub>H</bold>
</td>
</tr>
<tr>
<td align="center" valign="middle">1d</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">0.75</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.91</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">1.2</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">1.1</td>
</tr>
<tr>
<td align="center" valign="middle">02</td>
<td align="center" valign="middle">2/3</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">0.62</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">13.6</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">0.3</td>
</tr>
<tr>
<td align="center" valign="middle">03</td>
<td align="center" valign="middle">6</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">1.56</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">1.49</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">4.08</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">79</td>
</tr>
<tr>
<td align="center" valign="middle">04</td>
<td align="center" valign="middle">4</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">10.2</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">11.7</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">1.3</td>
</tr>
<tr>
<td align="center" valign="middle">05</td>
<td align="center" valign="middle">2/3</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">2.6</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">11.4</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">0.5</td>
</tr>
<tr>
<td align="center" valign="middle">06</td>
<td align="center" valign="middle">5</td>
<td align="center" valign="middle">Linr.<sup>
<xref ref-type="table-fn" rid="TFN4">d</xref>
</sup>
</td>
<td align="center" valign="middle">223</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">229</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">248</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">8.1</td>
</tr>
<tr>
<td align="center" valign="middle">07</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">0.94</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">1.1</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">1.1</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">12.2</td>
<td align="center" valign="middle">1</td>
</tr>
<tr>
<td align="center" valign="middle">10</td>
<td align="center" valign="middle">2/3/4</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">0.2</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.21</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">9.73</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">1.3</td>
</tr>
<tr>
<td align="center" valign="middle">11</td>
<td align="center" valign="middle">6</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">0.018</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.017</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.023</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.014</td>
<td align="center" valign="middle">4.3</td>
</tr>
<tr>
<td align="center" valign="middle">12<sup>
<xref ref-type="table-fn" rid="TFN1">a</xref>
</sup>
</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">0.047</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.046</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.04</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">0.8</td>
</tr>
<tr>
<td align="center" valign="middle">14</td>
<td align="center" valign="middle">2/4</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">2.6</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">2.44</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">wb<sup>
<xref ref-type="table-fn" rid="TFN6">f</xref>
</sup>
</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">0.9</td>
</tr>
<tr>
<td align="center" valign="middle">15</td>
<td align="center" valign="middle">2/3/4</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">0.32</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.31</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">22.2</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">0.7</td>
</tr>
<tr>
<td align="center" valign="middle">17</td>
<td align="center" valign="middle">3/4</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">0.15</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.13</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">5.1</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">0.4</td>
</tr>
<tr>
<td align="center" valign="middle">18</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">Linr.<sup>
<xref ref-type="table-fn" rid="TFN4">d</xref>
</sup>
</td>
<td align="center" valign="middle">0.32</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.35</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.37</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">0.8</td>
</tr>
<tr>
<td align="center" valign="middle">20</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">4.39</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">4.97</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">5.47</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">0.6</td>
</tr>
<tr>
<td align="center" valign="middle">MRed04</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">0.86</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.91</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">1.07</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">300</td>
<td align="center" valign="middle">0.4</td>
</tr>
<tr>
<td align="center" valign="middle">MRed05<sup>
<xref ref-type="table-fn" rid="TFN1">a</xref>
</sup>
</td>
<td align="center" valign="middle">2/3/4</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">0.91</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.31</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.89</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">0.5</td>
</tr>
<tr>
<td align="center" valign="middle">VHH-72<sup>
<xref ref-type="table-fn" rid="TFN2">b</xref>
</sup>
</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">86.2</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">96</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">124</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">6.52</td>
<td align="center" valign="middle">0.2</td>
</tr>
<tr>
<td align="center" valign="middle">ACE2<sup>
<xref ref-type="table-fn" rid="TFN2">b</xref>
</sup>
</td>
<td align="center" valign="middle">na<sup>
<xref ref-type="table-fn" rid="TFN4">d</xref>
</sup>
</td>
<td align="center" valign="middle">na</td>
<td align="center" valign="middle">153</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">18.3</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">131</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">351</td>
<td align="center" valign="middle">1.2</td>
</tr>
<tr>
<td colspan="4" align="left" valign="middle">
<bold>NTD-specific V<sub>h</sub>H</bold>
</td>
<td align="center" valign="middle" colspan="7"/>
</tr>
<tr>
<td align="center" valign="middle">SR01</td>
<td align="center" valign="middle">7</td>
<td align="center" valign="middle">Linr.<sup>
<xref ref-type="table-fn" rid="TFN4">d</xref>
</sup>
</td>
<td align="center" valign="middle">0.56</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.59</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.2</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.154</td>
<td align="center" valign="middle">3.4</td>
</tr>
<tr>
<td align="center" valign="middle">SR02</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">0.14</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.06</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.15</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">0.8</td>
</tr>
<tr>
<td align="center" valign="middle">SR03</td>
<td align="center" valign="middle">7</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">1.69</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">1.72</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">2.49</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">1.7</td>
</tr>
<tr>
<td align="center" valign="middle">SR04</td>
<td align="center" valign="middle">7</td>
<td align="center" valign="middle">Linr.<sup>
<xref ref-type="table-fn" rid="TFN4">d</xref>
</sup>
</td>
<td align="center" valign="middle">0.14</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.27</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.32</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">8.2</td>
</tr>
<tr>
<td align="center" valign="middle">SR13</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">3.6</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">5.8</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">7</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">1.8</td>
</tr>
<tr>
<td align="center" valign="middle">SR16</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">1.6</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">2.6</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">1.4</td>
</tr>
<tr>
<td align="center" valign="middle">MRed03</td>
<td align="center" valign="middle">8</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">0.51</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.36</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.67</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">15</td>
</tr>
<tr>
<td align="center" valign="middle">MRed06</td>
<td align="center" valign="middle">8</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">5.2</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">5.72</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">7.24</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">8.5</td>
</tr>
<tr>
<td align="center" valign="middle">MRed07</td>
<td align="center" valign="middle">9</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">0.11</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.26</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.23</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">132</td>
</tr>
<tr>
<td colspan="11" align="left" valign="middle">
<bold>S2-specific V<sub>h</sub>H</bold>
</td>
</tr>
<tr>
<td align="center" valign="middle">S2A3</td>
<td align="center" valign="middle">10</td>
<td align="center" valign="middle">Linr.<sup>
<xref ref-type="table-fn" rid="TFN4">d</xref>
</sup>
</td>
<td align="center" valign="middle">0.56</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">2.18</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.85</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">0.4</td>
</tr>
<tr>
<td align="center" valign="middle">S2A4</td>
<td align="center" valign="middle">11</td>
<td align="center" valign="middle">Linr.<sup>
<xref ref-type="table-fn" rid="TFN4">d</xref>
</sup>
</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">0.1</td>
</tr>
<tr>
<td align="center" valign="middle">S2F3</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">Linr.<sup>
<xref ref-type="table-fn" rid="TFN4">d</xref>
</sup>
</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">4.9</td>
<td align="center" valign="middle">2.7</td>
</tr>
<tr>
<td align="center" valign="middle">S2G3</td>
<td align="center" valign="middle">13</td>
<td align="center" valign="middle">Linr.<sup>
<xref ref-type="table-fn" rid="TFN4">d</xref>
</sup>
</td>
<td align="center" valign="middle">1.87</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">1.78</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">1.85</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">4.27</td>
<td align="center" valign="middle">0.3</td>
</tr>
<tr>
<td align="center" valign="middle">S2G4</td>
<td align="center" valign="middle">14</td>
<td align="center" valign="middle">Linr.<sup>
<xref ref-type="table-fn" rid="TFN4">d</xref>
</sup>
</td>
<td align="center" valign="middle">0.23</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">0.8</td>
<td align="center" valign="middle">0.3</td>
</tr>
<tr>
<td align="center" valign="middle">MRed11</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">Linr.<sup>
<xref ref-type="table-fn" rid="TFN4">d</xref>
</sup>
</td>
<td align="center" valign="middle">6.2</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">13.7</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">6.2</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">2.9</td>
</tr>
<tr>
<td align="center" valign="middle">MRed18</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">Linr.<sup>
<xref ref-type="table-fn" rid="TFN4">d</xref>
</sup>
</td>
<td align="center" valign="middle">6.03</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">12.9</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">6.48</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">22.5</td>
<td align="center" valign="middle">0.9</td>
</tr>
<tr>
<td align="center" valign="middle">MRed19</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">Linr.<sup>
<xref ref-type="table-fn" rid="TFN4">d</xref>
</sup>
</td>
<td align="center" valign="middle">9.07</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">20.2</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">8.07</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">24.6</td>
<td align="center" valign="middle">1.3</td>
</tr>
<tr>
<td align="center" valign="middle">MRed20</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">Linr.<sup>
<xref ref-type="table-fn" rid="TFN4">d</xref>
</sup>
</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">10.7</td>
<td align="center" valign="middle">4.7</td>
</tr>
<tr>
<td align="center" valign="middle">MRed22</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">0.3</td>
</tr>
<tr>
<td align="center" valign="middle">MRed25</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">Conf.<sup>
<xref ref-type="table-fn" rid="TFN3">c</xref>
</sup>
</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">2.29</td>
<td align="center" valign="middle">0.8</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN1">
<label>a</label>
<p id="P76">
<italic>K</italic>
<sub>D</sub>s were determined by flowing monomeric V<sub>h</sub>Hs over sensorchip surfaces immobilized with S, except for V<sub>h</sub>H 12 and MRed05, which were determined by flowing monomeric RBDs over V<sub>h</sub>H-Fc-captured surfaces (<italic>see</italic> <xref ref-type="supplementary-material" rid="SD2">Table S4</xref>)</p>
</fn>
<fn id="TFN2">
<label>b</label>
<p id="P77">VHH-72 benchmark is a SARS-CoV S-specific V<sub>h</sub>H that cross-reacts with SARS-CoV-2 S[<sup>
<xref ref-type="table-fn" rid="TFN8">1</xref>
</sup>]</p>
</fn>
<fn id="TFN3">
<label>c</label>
<p id="P78">His<sub>6</sub>-tagged monomeric ACE2 (ACE2-H<sub>6</sub>) was used for SPR assays, human Ig Fc-fused dimeric ACE2 (ACE2-Fc) for ELISA and cell binding assays by flow cytometry</p>
</fn>
<fn id="TFN4">
<label>d</label>
<p id="P79">Conf., conformational epitope; <sup>d</sup>Linr., linear epitope</p>
</fn>
<fn id="TFN5">
<label>e</label>
<p id="P80">ELISA was performed at 125 nM (1 μg/mL) V<sub>h</sub>H-Fc concentration (<italic>see</italic> <xref ref-type="fig" rid="F2">Fig.2A</xref>)</p>
</fn>
<fn id="TFN6">
<label>f</label>
<p id="P81">wb, weak binding</p>
</fn>
<fn id="TFN7">
<label>g</label>
<p id="P82">cell binding was performed by flow cytometry (FC) using V<sub>h</sub>H-Fcs; na, not applicable; nd, not determined.</p>
</fn>
<fn id="TFN8">
<label>1</label>
<p id="P83">Wrapp D, <italic>et al</italic>. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. <italic>Cell</italic> <bold>181</bold>, 1004-1015 e1015 (2020).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T2" position="float" orientation="portrait">
<label>Table 2</label>
<caption>
<title>Neutralization potencies of V<sub>h</sub>Hs against SARS-CoV-2 (Wuhan) and variants</title>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th rowspan="3" align="center" valign="middle">V<sub>h</sub>H</th>
<th rowspan="3" align="center" valign="middle">Epitope bin</th>
<th colspan="2" align="center" valign="middle">SVNA <italic>IC</italic>
<sub>50</sub> (nM)<sup>
<xref ref-type="table-fn" rid="TFN11">c</xref>
</sup>
</th>
<th colspan="2" align="center" valign="middle">PVNA <italic>IC</italic>
<sub>50</sub> (nM)<sup>
<xref ref-type="table-fn" rid="TFN11">c</xref>
</sup>
</th>
<th colspan="3" align="center" valign="middle">LVNA <italic>IC</italic>
<sub>50</sub> (nM)<sup>
<xref ref-type="table-fn" rid="TFN11">c</xref>
</sup>
</th>
</tr>
<tr>
<th rowspan="2" align="center" valign="middle">V<sub>h</sub>H</th>
<th rowspan="2" align="center" valign="middle">V<sub>h</sub>H-Fc</th>
<th rowspan="2" align="center" valign="middle">V<sub>h</sub>H</th>
<th rowspan="2" align="center" valign="middle">V<sub>h</sub>H-Fc</th>
<th colspan="3" align="center" valign="middle">V<sub>h</sub>H-Fc</th>
</tr>
<tr>
<th align="center" valign="middle">Wuhan</th>
<th align="center" valign="middle">Alpha</th>
<th align="center" valign="middle">Beta</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="9" align="left" valign="middle">
<bold>RBD-specific V<sub>h</sub>H</bold>
</td>
</tr>
<tr>
<td align="center" valign="middle">1d</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">8.6</td>
<td align="center" valign="middle">5.4</td>
<td align="center" valign="middle">50</td>
<td align="center" valign="middle">16.7</td>
<td align="center" valign="middle">1.94</td>
<td align="center" valign="middle">0.37</td>
<td align="center" valign="middle">2.14</td>
</tr>
<tr>
<td align="center" valign="middle">02</td>
<td align="center" valign="middle">2/3</td>
<td align="center" valign="middle">5.1</td>
<td align="center" valign="middle">5</td>
<td align="center" valign="middle">43</td>
<td align="center" valign="middle">6.5</td>
<td align="center" valign="middle">0.12</td>
<td align="center" valign="middle">0.09</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">03</td>
<td align="center" valign="middle">6</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">910</td>
<td align="center" valign="middle">26.6</td>
<td align="center" valign="middle">58</td>
<td align="center" valign="middle">16</td>
<td align="center" valign="middle">62</td>
</tr>
<tr>
<td align="center" valign="middle">04</td>
<td align="center" valign="middle">4</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">11.7</td>
<td align="center" valign="middle">111</td>
<td align="center" valign="middle">26.6</td>
<td align="center" valign="middle">1.65</td>
<td align="center" valign="middle">2.3</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">05</td>
<td align="center" valign="middle">2/3</td>
<td align="center" valign="middle">9.5</td>
<td align="center" valign="middle">6.7</td>
<td align="center" valign="middle">79</td>
<td align="center" valign="middle">2.3</td>
<td align="center" valign="middle">0.0008</td>
<td align="center" valign="middle">0.03</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">06</td>
<td align="center" valign="middle">5</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">2500</td>
<td align="center" valign="middle">24.2</td>
<td align="center" valign="middle">76</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">07</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">7.5</td>
<td align="center" valign="middle">6.8</td>
<td align="center" valign="middle">44</td>
<td align="center" valign="middle">15.6</td>
<td align="center" valign="middle">6.15</td>
<td align="center" valign="middle">0.42</td>
<td align="center" valign="middle">3.18</td>
</tr>
<tr>
<td align="center" valign="middle">10</td>
<td align="center" valign="middle">2/3/4</td>
<td align="center" valign="middle">16.1</td>
<td align="center" valign="middle">7.7</td>
<td align="center" valign="middle">48</td>
<td align="center" valign="middle">2.9</td>
<td align="center" valign="middle">1.28</td>
<td align="center" valign="middle">0.47</td>
<td align="center" valign="middle">2.25</td>
</tr>
<tr>
<td align="center" valign="middle">11</td>
<td align="center" valign="middle">6</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">9.7</td>
<td align="center" valign="middle">61</td>
<td align="center" valign="middle">30.8</td>
<td align="center" valign="middle">9.9</td>
<td align="center" valign="middle">2.3</td>
<td align="center" valign="middle">18.5</td>
</tr>
<tr>
<td align="center" valign="middle">12<sup>
<xref ref-type="table-fn" rid="TFN9">a</xref>
</sup>
</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">7.3</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">6.7</td>
<td align="center" valign="middle">2.82</td>
<td align="center" valign="middle">1.35</td>
<td align="center" valign="middle">2.62</td>
</tr>
<tr>
<td align="center" valign="middle">14</td>
<td align="center" valign="middle">2/4</td>
<td align="center" valign="middle">21.3</td>
<td align="center" valign="middle">9.9</td>
<td align="center" valign="middle">84</td>
<td align="center" valign="middle">6.6</td>
<td align="center" valign="middle">3.1</td>
<td align="center" valign="middle">0.88</td>
<td align="center" valign="middle">32.8</td>
</tr>
<tr>
<td align="center" valign="middle">15</td>
<td align="center" valign="middle">2/3/4</td>
<td align="center" valign="middle">12.1</td>
<td align="center" valign="middle">8.1</td>
<td align="center" valign="middle">39</td>
<td align="center" valign="middle">5.7</td>
<td align="center" valign="middle">0.73</td>
<td align="center" valign="middle">0.16</td>
<td align="center" valign="middle">0.43</td>
</tr>
<tr>
<td align="center" valign="middle">17</td>
<td align="center" valign="middle">3/4</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">8.6</td>
<td align="center" valign="middle">44</td>
<td align="center" valign="middle">6.3</td>
<td align="center" valign="middle">2.82</td>
<td align="center" valign="middle">0.61</td>
<td align="center" valign="middle">34.7</td>
</tr>
<tr>
<td align="center" valign="middle">18</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">8.9</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">41</td>
<td align="center" valign="middle">28.7</td>
<td align="center" valign="middle">6.4</td>
<td align="center" valign="middle">2.82</td>
<td align="center" valign="middle">9.48</td>
</tr>
<tr>
<td align="center" valign="middle">20</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">5.1</td>
<td align="center" valign="middle">8.7</td>
<td align="center" valign="middle">196</td>
<td align="center" valign="middle">7.6</td>
<td align="center" valign="middle">11.2</td>
<td align="center" valign="middle">1.94</td>
<td align="center" valign="middle">2.88</td>
</tr>
<tr>
<td align="center" valign="middle">MRed04</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">6.1</td>
<td align="center" valign="middle">8.3</td>
<td align="center" valign="middle">62</td>
<td align="center" valign="middle">3.8</td>
<td align="center" valign="middle">9.61</td>
<td align="center" valign="middle">4.5</td>
<td align="center" valign="middle">5.73</td>
</tr>
<tr>
<td align="center" valign="middle">MRed05<sup>
<xref ref-type="table-fn" rid="TFN9">a</xref>
</sup>
</td>
<td align="center" valign="middle">2/3/4</td>
<td align="center" valign="middle">15.3</td>
<td align="center" valign="middle">6.1</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">10</td>
<td align="center" valign="middle">0.17</td>
<td align="center" valign="middle">0.13</td>
<td align="center" valign="middle">0.11</td>
</tr>
<tr>
<td align="center" valign="middle">VHH-72<sup>
<xref ref-type="table-fn" rid="TFN10">b</xref>
</sup>
</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">59</td>
<td align="center" valign="middle">7.2</td>
<td align="center" valign="middle">490</td>
<td align="center" valign="middle">25</td>
<td align="center" valign="middle">8.46</td>
<td align="center" valign="middle">1.86</td>
<td align="center" valign="middle">9.34</td>
</tr>
<tr>
<td colspan="9" align="left" valign="middle">
<bold>NTD-specific V<sub>h</sub>H</bold>
</td>
</tr>
<tr>
<td align="center" valign="middle">SR01</td>
<td align="center" valign="middle">7</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">6.6</td>
<td align="center" valign="middle">188</td>
<td align="center" valign="middle">19.5</td>
<td align="center" valign="middle">9.42</td>
<td align="center" valign="middle">3.77</td>
<td align="center" valign="middle">70.3</td>
</tr>
<tr>
<td align="center" valign="middle">SR02</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">5.8</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">11.3</td>
<td align="center" valign="middle">14.13</td>
<td align="center" valign="middle">9.05</td>
<td align="center" valign="middle">~300</td>
</tr>
<tr>
<td align="center" valign="middle">SR03</td>
<td align="center" valign="middle">7</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">269</td>
<td align="center" valign="middle">29.4</td>
<td align="center" valign="middle">~500</td>
<td align="center" valign="middle">22.2</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">SR04</td>
<td align="center" valign="middle">7</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">~500</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">SR13</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">23.8</td>
<td align="center" valign="middle">41</td>
<td align="center" valign="middle">86.9</td>
<td align="center" valign="middle">~100</td>
<td align="center" valign="middle">~100</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">SR16</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">17.5</td>
<td align="center" valign="middle">54.2</td>
<td align="center" valign="middle">17.8</td>
<td align="center" valign="middle">100</td>
</tr>
<tr>
<td align="center" valign="middle">MRed03</td>
<td align="center" valign="middle">8</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">MRed06</td>
<td align="center" valign="middle">8</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">MRed07</td>
<td align="center" valign="middle">9</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="left" valign="middle" colspan="9">
<bold>S-specific V<sub>h</sub>H</bold>
</td>
</tr>
<tr>
<td align="center" valign="middle">S2A3</td>
<td align="center" valign="middle">10</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">12.2</td>
<td align="center" valign="middle">31</td>
<td align="center" valign="middle">54</td>
</tr>
<tr>
<td align="center" valign="middle">S2A4</td>
<td align="center" valign="middle">11</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">S2F3</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">S2G3</td>
<td align="center" valign="middle">13</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">~200</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">S2G4</td>
<td align="center" valign="middle">14</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">~200</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">MRed11</td>
<td align="center" valign="middle">nd</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">MRed18</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">~400</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">MRed19</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">MRed20</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">MRed22</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="center" valign="middle">MRed25</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN9">
<label>a</label>
<p id="P84">The neutralization of nanobodies 12 and MRed05 were not assessed in their V<sub>h</sub>H format due to insufficient expression</p>
</fn>
<fn id="TFN10">
<label>b</label>
<p id="P85">VHH-72 benchmark is SARS-CoV S-specific V<sub>h</sub>H that cross-reacts with SARS-CoV-2 S[1]</p>
</fn>
<fn id="TFN11">
<label>c</label>
<p id="P86">SVNA, PVNA, LVNA, surrogate, pseudo-typed and authentic virus neutralization assay, respectively; Dash indicates lack of neutralization; nd, not determined.</p>
</fn>
<fn id="TFN12">
<label>1</label>
<p id="P87">Wrapp D, <italic>et al</italic>. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. <italic>Cell</italic> <bold>181</bold>, 1004-1015 e1015 (2020).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
